Movatterモバイル変換


[0]ホーム

URL:


US20100168148A1 - Pharmaceutical formulation containing gelling agent - Google Patents

Pharmaceutical formulation containing gelling agent
Download PDF

Info

Publication number
US20100168148A1
US20100168148A1US12/653,115US65311509AUS2010168148A1US 20100168148 A1US20100168148 A1US 20100168148A1US 65311509 AUS65311509 AUS 65311509AUS 2010168148 A1US2010168148 A1US 2010168148A1
Authority
US
United States
Prior art keywords
dosage form
controlled release
oral dosage
release oral
opioid analgesic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/653,115
Inventor
Curtis Wright
Benjamin Oshlack
Christopher Breder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Purdue Pharma LP
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=29218415&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20100168148(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to US12/653,115priorityCriticalpatent/US20100168148A1/en
Application filed by IndividualfiledCriticalIndividual
Publication of US20100168148A1publicationCriticalpatent/US20100168148A1/en
Priority to US13/349,449prioritypatent/US8337888B2/en
Assigned to PURDUE PHARMACEUTICALS L.P., THE P.F. LABORATORIES, INC., PURDUE PHARMA L.P.reassignmentPURDUE PHARMACEUTICALS L.P.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: PURDUE PHARMA L.P.
Priority to US13/726,324prioritypatent/US9060976B2/en
Priority to US13/905,922prioritypatent/US8609683B2/en
Priority to US13/905,931prioritypatent/US8529948B1/en
Priority to US14/243,580prioritypatent/US20140213606A1/en
Priority to US14/255,502prioritypatent/US8871265B2/en
Priority to US14/460,134prioritypatent/US9034376B2/en
Priority to US14/460,170prioritypatent/US20140371257A1/en
Priority to US14/470,631prioritypatent/US20150005331A1/en
Priority to US14/470,662prioritypatent/US20150031718A1/en
Priority to US14/484,077prioritypatent/US9044435B2/en
Priority to US14/605,034prioritypatent/US20150140083A1/en
Priority to US14/611,716prioritypatent/US20150147391A1/en
Priority to US14/658,285prioritypatent/US9387173B2/en
Priority to US14/728,601prioritypatent/US20150283250A1/en
Priority to US14/730,016prioritypatent/US20150283130A1/en
Priority to US14/730,003prioritypatent/US20150283129A1/en
Priority to US14/730,002prioritypatent/US20150283128A1/en
Priority to US14/730,021prioritypatent/US20150273065A1/en
Priority to US14/730,017prioritypatent/US20150273064A1/en
Priority to US14/733,654prioritypatent/US20150265606A1/en
Priority to US14/733,639prioritypatent/US20150265604A1/en
Priority to US14/733,634prioritypatent/US20150265603A1/en
Priority to US14/733,618prioritypatent/US20150265602A1/en
Priority to US14/733,659prioritypatent/US20150265607A1/en
Priority to US14/733,647prioritypatent/US20150265605A1/en
Priority to US14/846,021prioritypatent/US20150374631A1/en
Priority to US14/851,727prioritypatent/US9517207B2/en
Priority to US14/852,236prioritypatent/US20160058716A1/en
Priority to US14/851,575prioritypatent/US9387174B2/en
Priority to US14/852,157prioritypatent/US20160000712A1/en
Priority to US14/856,392prioritypatent/US20160000776A1/en
Priority to US14/856,386prioritypatent/US20160000718A1/en
Priority to US14/856,394prioritypatent/US20160000717A1/en
Priority to US14/856,388prioritypatent/US20160000719A1/en
Priority to US15/345,979prioritypatent/US10130586B2/en
Priority to US15/354,473prioritypatent/US20170065524A1/en
Priority to US15/803,370prioritypatent/US10206881B2/en
Priority to US16/229,188prioritypatent/US10537526B2/en
Assigned to PURDUE PHARMA L.P.reassignmentPURDUE PHARMA L.P.ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).Assignors: PURDUE PHARMA TECHNOLOGIES, INC., THE P.F. LABORATORIES, INC.
Abandonedlegal-statusCriticalCurrent

Links

Classifications

Definitions

Landscapes

Abstract

Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Description

Claims (21)

US12/653,1152001-08-062009-12-08Pharmaceutical formulation containing gelling agentAbandonedUS20100168148A1 (en)

Priority Applications (40)

Application NumberPriority DateFiling DateTitle
US12/653,115US20100168148A1 (en)2001-08-062009-12-08Pharmaceutical formulation containing gelling agent
US13/349,449US8337888B2 (en)2001-08-062012-01-12Pharmaceutical formulation containing gelling agent
US13/726,324US9060976B2 (en)2001-08-062012-12-24Pharmaceutical formulation containing gelling agent
US13/905,922US8609683B2 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US13/905,931US8529948B1 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US14/243,580US20140213606A1 (en)2001-08-062014-04-02Pharmaceutical Formulation Containing Gelling Agent
US14/255,502US8871265B2 (en)2001-08-062014-04-17Pharmaceutical formulation containing gelling agent
US14/460,170US20140371257A1 (en)2001-08-062014-08-14Pharmaceutical Formulation Containing Gelling Agent
US14/460,134US9034376B2 (en)2001-08-062014-08-14Pharmaceutical formulation containing gelling agent
US14/470,631US20150005331A1 (en)2001-08-062014-08-27Pharmaceutical Formulation Containing Gelling Agent
US14/470,662US20150031718A1 (en)2001-08-062014-08-27Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US14/484,077US9044435B2 (en)2001-08-062014-09-11Pharmaceutical formulation containing gelling agent
US14/605,034US20150140083A1 (en)2001-08-062015-01-26Pharmaceutical Formulation Containing Gelling Agent
US14/611,716US20150147391A1 (en)2001-08-062015-02-02Pharmaceutical Formulation Containing Gelling Agent
US14/658,285US9387173B2 (en)2001-08-062015-03-16Pharmaceutical formulation containing gelling agent
US14/728,601US20150283250A1 (en)2001-08-062015-06-02Pharmaceutical Formulation Containing Gelling Agent
US14/730,016US20150283130A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,003US20150283129A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,002US20150283128A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,021US20150273065A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,017US20150273064A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/733,654US20150265606A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,618US20150265602A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,659US20150265607A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,639US20150265604A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,647US20150265605A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,634US20150265603A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/846,021US20150374631A1 (en)2001-08-062015-09-04Pharmaceutical Formulation Containing Gelling Agent
US14/851,575US9387174B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/852,236US20160058716A1 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/851,727US9517207B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/852,157US20160000712A1 (en)2001-08-062015-09-11Pharmaceutical Formulation Containing Gelling Agent
US14/856,388US20160000719A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,392US20160000776A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,386US20160000718A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,394US20160000717A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US15/345,979US10130586B2 (en)2001-08-062016-11-08Pharmaceutical formulation containing gelling agent
US15/354,473US20170065524A1 (en)2001-08-062016-11-17Pharmaceutical Formulation Containing Gelling Agent
US15/803,370US10206881B2 (en)2001-08-062017-11-03Pharmaceutical formulation containing gelling agent
US16/229,188US10537526B2 (en)2001-08-062018-12-21Pharmaceutical formulation containing gelling agent

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US31053401P2001-08-062001-08-06
US10/214,412US20030068375A1 (en)2001-08-062002-08-06Pharmaceutical formulation containing gelling agent
US12/653,115US20100168148A1 (en)2001-08-062009-12-08Pharmaceutical formulation containing gelling agent

Related Parent Applications (1)

Application NumberTitlePriority DateFiling Date
US10/214,412ContinuationUS20030068375A1 (en)2001-08-062002-08-06Pharmaceutical formulation containing gelling agent

Related Child Applications (1)

Application NumberTitlePriority DateFiling Date
US13/349,449ContinuationUS8337888B2 (en)2001-08-062012-01-12Pharmaceutical formulation containing gelling agent

Publications (1)

Publication NumberPublication Date
US20100168148A1true US20100168148A1 (en)2010-07-01

Family

ID=29218415

Family Applications (69)

Application NumberTitlePriority DateFiling Date
US10/214,412AbandonedUS20030068375A1 (en)2001-08-062002-08-06Pharmaceutical formulation containing gelling agent
US12/262,015Expired - Fee RelatedUS8389007B2 (en)2001-08-062008-10-30Pharmaceutical composition containing gelling agent
US12/653,115AbandonedUS20100168148A1 (en)2001-08-062009-12-08Pharmaceutical formulation containing gelling agent
US13/349,449Expired - Fee RelatedUS8337888B2 (en)2001-08-062012-01-12Pharmaceutical formulation containing gelling agent
US13/726,324Expired - Fee RelatedUS9060976B2 (en)2001-08-062012-12-24Pharmaceutical formulation containing gelling agent
US13/765,368Expired - Fee RelatedUS9040084B2 (en)2001-08-062013-02-12Pharmaceutical formulation containing gelling agent
US13/890,874Expired - Fee RelatedUS9308170B2 (en)2001-08-062013-05-09Pharmaceutical formulation containing gelling agent
US13/905,922Expired - LifetimeUS8609683B2 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US13/905,931Expired - LifetimeUS8529948B1 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US13/946,418Expired - Fee RelatedUS8999961B2 (en)2001-08-062013-07-19Pharmaceutical formulation containing gelling agent
US14/243,580AbandonedUS20140213606A1 (en)2001-08-062014-04-02Pharmaceutical Formulation Containing Gelling Agent
US14/255,502Expired - LifetimeUS8871265B2 (en)2001-08-062014-04-17Pharmaceutical formulation containing gelling agent
US14/460,134Expired - Fee RelatedUS9034376B2 (en)2001-08-062014-08-14Pharmaceutical formulation containing gelling agent
US14/460,170AbandonedUS20140371257A1 (en)2001-08-062014-08-14Pharmaceutical Formulation Containing Gelling Agent
US14/470,631AbandonedUS20150005331A1 (en)2001-08-062014-08-27Pharmaceutical Formulation Containing Gelling Agent
US14/484,077Expired - Fee RelatedUS9044435B2 (en)2001-08-062014-09-11Pharmaceutical formulation containing gelling agent
US14/605,034AbandonedUS20150140083A1 (en)2001-08-062015-01-26Pharmaceutical Formulation Containing Gelling Agent
US14/610,156Expired - Fee RelatedUS9308171B2 (en)2001-08-062015-01-30Pharmaceutical formulation containing gelling agent
US14/611,716AbandonedUS20150147391A1 (en)2001-08-062015-02-02Pharmaceutical Formulation Containing Gelling Agent
US14/638,685Expired - LifetimeUS9867783B2 (en)2001-08-062015-03-04Pharmaceutical formulation containing gelling agent
US14/658,285Expired - Fee RelatedUS9387173B2 (en)2001-08-062015-03-16Pharmaceutical formulation containing gelling agent
US14/728,601GrantedUS20150283250A1 (en)2001-08-062015-06-02Pharmaceutical Formulation Containing Gelling Agent
US14/730,002AbandonedUS20150283128A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,021AbandonedUS20150273065A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,017AbandonedUS20150273064A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,003AbandonedUS20150283129A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,016AbandonedUS20150283130A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/733,647AbandonedUS20150265605A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,659GrantedUS20150265607A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,654AbandonedUS20150265606A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,618GrantedUS20150265602A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,634AbandonedUS20150265603A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,639AbandonedUS20150265604A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/846,021AbandonedUS20150374631A1 (en)2001-08-062015-09-04Pharmaceutical Formulation Containing Gelling Agent
US14/852,157AbandonedUS20160000712A1 (en)2001-08-062015-09-11Pharmaceutical Formulation Containing Gelling Agent
US14/851,575Expired - Fee RelatedUS9387174B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/852,236AbandonedUS20160058716A1 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/851,727Expired - Fee RelatedUS9517207B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/856,386AbandonedUS20160000718A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,388AbandonedUS20160000719A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,392AbandonedUS20160000776A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,394AbandonedUS20160000717A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US15/013,628Expired - LifetimeUS10071057B2 (en)2001-08-062016-02-02Pharmaceutical formulation containing gelling agent
US15/015,708AbandonedUS20160151502A1 (en)2001-08-062016-02-04Pharmaceutical Formulation Containing Gelling Agent
US15/015,722Expired - LifetimeUS9693961B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,769Expired - LifetimeUS9861582B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,763Expired - LifetimeUS10076497B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,735Expired - LifetimeUS9872836B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/019,304Expired - LifetimeUS9968559B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/019,315AbandonedUS20160151290A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,281Expired - LifetimeUS10064824B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/019,222AbandonedUS20160151360A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,321AbandonedUS20160151291A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,195Expired - LifetimeUS9867784B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/284,711Expired - LifetimeUS9757341B2 (en)2001-08-062016-10-04Pharmaceutical formulation containing gelling agent
US15/284,706Expired - LifetimeUS9877924B2 (en)2001-08-062016-10-04Pharmaceutical formulation containing gelling agent
US15/345,979Expired - LifetimeUS10130586B2 (en)2001-08-062016-11-08Pharmaceutical formulation containing gelling agent
US15/354,473AbandonedUS20170065524A1 (en)2001-08-062016-11-17Pharmaceutical Formulation Containing Gelling Agent
US15/354,538Expired - LifetimeUS9861583B2 (en)2001-08-062016-11-17Pharmaceutical formulation containing gelling agent
US15/637,703AbandonedUS20170296533A1 (en)2001-08-062017-06-29Pharmaceutical Formulation Containing Gelling Agent
US15/702,127Expired - LifetimeUS10064825B2 (en)2001-08-062017-09-12Pharmaceutical formulation containing gelling agent
US15/803,370Expired - LifetimeUS10206881B2 (en)2001-08-062017-11-03Pharmaceutical formulation containing gelling agent
US15/865,832AbandonedUS20180125788A1 (en)2001-08-062018-01-09Pharmaceutical Formulation Containing Gelling Agent
US15/877,917AbandonedUS20180147151A1 (en)2001-08-062018-01-23Pharmaceutical Formulation Containing Gelling Agent
US16/121,242Expired - Fee RelatedUS10500160B2 (en)2001-08-062018-09-04Pharmaceutical formulation containing gelling agent
US16/133,993AbandonedUS20190015341A1 (en)2001-08-062018-09-18Pharmaceutical Formulation Containing Gelling Agent
US16/163,076AbandonedUS20190110996A1 (en)2001-08-062018-10-17Pharmaceutical Formulation Containing Gelling Agent
US16/229,188Expired - Fee RelatedUS10537526B2 (en)2001-08-062018-12-21Pharmaceutical formulation containing gelling agent
US16/666,810Expired - LifetimeUS11135171B2 (en)2001-08-062019-10-29Pharmaceutical formulation containing gelling agent

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
US10/214,412AbandonedUS20030068375A1 (en)2001-08-062002-08-06Pharmaceutical formulation containing gelling agent
US12/262,015Expired - Fee RelatedUS8389007B2 (en)2001-08-062008-10-30Pharmaceutical composition containing gelling agent

Family Applications After (66)

Application NumberTitlePriority DateFiling Date
US13/349,449Expired - Fee RelatedUS8337888B2 (en)2001-08-062012-01-12Pharmaceutical formulation containing gelling agent
US13/726,324Expired - Fee RelatedUS9060976B2 (en)2001-08-062012-12-24Pharmaceutical formulation containing gelling agent
US13/765,368Expired - Fee RelatedUS9040084B2 (en)2001-08-062013-02-12Pharmaceutical formulation containing gelling agent
US13/890,874Expired - Fee RelatedUS9308170B2 (en)2001-08-062013-05-09Pharmaceutical formulation containing gelling agent
US13/905,922Expired - LifetimeUS8609683B2 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US13/905,931Expired - LifetimeUS8529948B1 (en)2001-08-062013-05-30Pharmaceutical formulation containing gelling agent
US13/946,418Expired - Fee RelatedUS8999961B2 (en)2001-08-062013-07-19Pharmaceutical formulation containing gelling agent
US14/243,580AbandonedUS20140213606A1 (en)2001-08-062014-04-02Pharmaceutical Formulation Containing Gelling Agent
US14/255,502Expired - LifetimeUS8871265B2 (en)2001-08-062014-04-17Pharmaceutical formulation containing gelling agent
US14/460,134Expired - Fee RelatedUS9034376B2 (en)2001-08-062014-08-14Pharmaceutical formulation containing gelling agent
US14/460,170AbandonedUS20140371257A1 (en)2001-08-062014-08-14Pharmaceutical Formulation Containing Gelling Agent
US14/470,631AbandonedUS20150005331A1 (en)2001-08-062014-08-27Pharmaceutical Formulation Containing Gelling Agent
US14/484,077Expired - Fee RelatedUS9044435B2 (en)2001-08-062014-09-11Pharmaceutical formulation containing gelling agent
US14/605,034AbandonedUS20150140083A1 (en)2001-08-062015-01-26Pharmaceutical Formulation Containing Gelling Agent
US14/610,156Expired - Fee RelatedUS9308171B2 (en)2001-08-062015-01-30Pharmaceutical formulation containing gelling agent
US14/611,716AbandonedUS20150147391A1 (en)2001-08-062015-02-02Pharmaceutical Formulation Containing Gelling Agent
US14/638,685Expired - LifetimeUS9867783B2 (en)2001-08-062015-03-04Pharmaceutical formulation containing gelling agent
US14/658,285Expired - Fee RelatedUS9387173B2 (en)2001-08-062015-03-16Pharmaceutical formulation containing gelling agent
US14/728,601GrantedUS20150283250A1 (en)2001-08-062015-06-02Pharmaceutical Formulation Containing Gelling Agent
US14/730,002AbandonedUS20150283128A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,021AbandonedUS20150273065A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,017AbandonedUS20150273064A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,003AbandonedUS20150283129A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/730,016AbandonedUS20150283130A1 (en)2001-08-062015-06-03Pharmaceutical Formulation Containing Gelling Agent
US14/733,647AbandonedUS20150265605A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,659GrantedUS20150265607A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,654AbandonedUS20150265606A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,618GrantedUS20150265602A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,634AbandonedUS20150265603A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/733,639AbandonedUS20150265604A1 (en)2001-08-062015-06-08Pharmaceutical Formulation Containing Gelling Agent
US14/846,021AbandonedUS20150374631A1 (en)2001-08-062015-09-04Pharmaceutical Formulation Containing Gelling Agent
US14/852,157AbandonedUS20160000712A1 (en)2001-08-062015-09-11Pharmaceutical Formulation Containing Gelling Agent
US14/851,575Expired - Fee RelatedUS9387174B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/852,236AbandonedUS20160058716A1 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/851,727Expired - Fee RelatedUS9517207B2 (en)2001-08-062015-09-11Pharmaceutical formulation containing gelling agent
US14/856,386AbandonedUS20160000718A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,388AbandonedUS20160000719A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,392AbandonedUS20160000776A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US14/856,394AbandonedUS20160000717A1 (en)2001-08-062015-09-16Pharmaceutical Formulation Containing Gelling Agent
US15/013,628Expired - LifetimeUS10071057B2 (en)2001-08-062016-02-02Pharmaceutical formulation containing gelling agent
US15/015,708AbandonedUS20160151502A1 (en)2001-08-062016-02-04Pharmaceutical Formulation Containing Gelling Agent
US15/015,722Expired - LifetimeUS9693961B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,769Expired - LifetimeUS9861582B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,763Expired - LifetimeUS10076497B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/015,735Expired - LifetimeUS9872836B2 (en)2001-08-062016-02-04Pharmaceutical formulation containing gelling agent
US15/019,304Expired - LifetimeUS9968559B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/019,315AbandonedUS20160151290A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,281Expired - LifetimeUS10064824B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/019,222AbandonedUS20160151360A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,321AbandonedUS20160151291A1 (en)2001-08-062016-02-09Pharmaceutical Formulation Containing Gelling Agent
US15/019,195Expired - LifetimeUS9867784B2 (en)2001-08-062016-02-09Pharmaceutical formulation containing gelling agent
US15/284,711Expired - LifetimeUS9757341B2 (en)2001-08-062016-10-04Pharmaceutical formulation containing gelling agent
US15/284,706Expired - LifetimeUS9877924B2 (en)2001-08-062016-10-04Pharmaceutical formulation containing gelling agent
US15/345,979Expired - LifetimeUS10130586B2 (en)2001-08-062016-11-08Pharmaceutical formulation containing gelling agent
US15/354,473AbandonedUS20170065524A1 (en)2001-08-062016-11-17Pharmaceutical Formulation Containing Gelling Agent
US15/354,538Expired - LifetimeUS9861583B2 (en)2001-08-062016-11-17Pharmaceutical formulation containing gelling agent
US15/637,703AbandonedUS20170296533A1 (en)2001-08-062017-06-29Pharmaceutical Formulation Containing Gelling Agent
US15/702,127Expired - LifetimeUS10064825B2 (en)2001-08-062017-09-12Pharmaceutical formulation containing gelling agent
US15/803,370Expired - LifetimeUS10206881B2 (en)2001-08-062017-11-03Pharmaceutical formulation containing gelling agent
US15/865,832AbandonedUS20180125788A1 (en)2001-08-062018-01-09Pharmaceutical Formulation Containing Gelling Agent
US15/877,917AbandonedUS20180147151A1 (en)2001-08-062018-01-23Pharmaceutical Formulation Containing Gelling Agent
US16/121,242Expired - Fee RelatedUS10500160B2 (en)2001-08-062018-09-04Pharmaceutical formulation containing gelling agent
US16/133,993AbandonedUS20190015341A1 (en)2001-08-062018-09-18Pharmaceutical Formulation Containing Gelling Agent
US16/163,076AbandonedUS20190110996A1 (en)2001-08-062018-10-17Pharmaceutical Formulation Containing Gelling Agent
US16/229,188Expired - Fee RelatedUS10537526B2 (en)2001-08-062018-12-21Pharmaceutical formulation containing gelling agent
US16/666,810Expired - LifetimeUS11135171B2 (en)2001-08-062019-10-29Pharmaceutical formulation containing gelling agent

Country Status (1)

CountryLink
US (69)US20030068375A1 (en)

Cited By (49)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US20090081290A1 (en)*2006-08-252009-03-26Purdue Pharma L.P.Tamper resistant dosage forms
US20110038930A1 (en)*2009-07-222011-02-17Grunenthal GmbhHot-melt extruded pharmaceutical dosage form
US8372432B2 (en)2008-03-112013-02-12Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8377453B2 (en)2008-03-112013-02-19Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8597681B2 (en)2009-12-222013-12-03Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US8658631B1 (en)2011-05-172014-02-25Mallinckrodt LlcCombination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8722086B2 (en)2007-03-072014-05-13Gruenenthal GmbhDosage form with impeded abuse
US8741885B1 (en)2011-05-172014-06-03Mallinckrodt LlcGastric retentive extended release pharmaceutical compositions
US8808745B2 (en)2001-09-212014-08-19Egalet Ltd.Morphine polymer release system
US8858963B1 (en)2011-05-172014-10-14Mallinckrodt LlcTamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8877241B2 (en)2003-03-262014-11-04Egalet Ltd.Morphine controlled release system
US9005660B2 (en)2009-02-062015-04-14Egalet Ltd.Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en)2009-06-242015-05-05Egalet Ltd.Formulations and methods for the controlled release of active drug substances
US9044402B2 (en)2012-07-062015-06-02Egalet Ltd.Abuse-deterrent pharmaceutical compositions for controlled release
US9161917B2 (en)2008-05-092015-10-20Grünenthal GmbHProcess for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9198861B2 (en)2009-12-222015-12-01Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9301918B2 (en)2013-03-152016-04-05Mallinckrodt LlcAbuse deterrent solid dosage form for immediate release with functional score
US9629807B2 (en)2003-08-062017-04-25Grünenthal GmbHAbuse-proofed dosage form
US9636303B2 (en)2010-09-022017-05-02Gruenenthal GmbhTamper resistant dosage form comprising an anionic polymer
US9642809B2 (en)2007-06-042017-05-09Egalet Ltd.Controlled release pharmaceutical compositions for prolonged effect
US9655853B2 (en)2012-02-282017-05-23Grünenthal GmbHTamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en)2002-06-172017-06-13Grünenthal GmbHAbuse-proofed dosage form
US9694080B2 (en)2001-09-212017-07-04Egalet Ltd.Polymer release system
US9730885B2 (en)2012-07-122017-08-15Mallinckrodt LlcExtended release, abuse deterrent pharmaceutical compositions
US9737490B2 (en)2013-05-292017-08-22Grünenthal GmbHTamper resistant dosage form with bimodal release profile
US9750701B2 (en)2008-01-252017-09-05Grünenthal GmbHPharmaceutical dosage form
US9849125B1 (en)2015-11-032017-12-26Banner Lifie Sciences LLCAnti-overingestion dosage forms
US9855263B2 (en)2015-04-242018-01-02Grünenthal GmbHTamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en)2014-05-262018-01-23Grünenthal GmbHMultiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en)2014-05-122018-03-13Grünenthal GmbHTamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en)2009-07-222018-03-27Grünenthal GmbHOxidation-stabilized tamper-resistant dosage form
US9993422B2 (en)2012-04-182018-06-12SpecGx LLCImmediate release, abuse deterrent pharmaceutical compositions
US10058548B2 (en)2003-08-062018-08-28Grünenthal GmbHAbuse-proofed dosage form
US10064945B2 (en)2012-05-112018-09-04Gruenenthal GmbhThermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10130591B2 (en)2003-08-062018-11-20Grünenthal GmbHAbuse-proofed dosage form
US10154966B2 (en)2013-05-292018-12-18Grünenthal GmbHTamper-resistant dosage form containing one or more particles
US10201502B2 (en)2011-07-292019-02-12Gruenenthal GmbhTamper-resistant tablet providing immediate drug release
US10300141B2 (en)2010-09-022019-05-28Grünenthal GmbHTamper resistant dosage form comprising inorganic salt
US10335375B2 (en)2017-05-302019-07-02Patheon Softgels, Inc.Anti-overingestion abuse deterrent compositions
US10335373B2 (en)2012-04-182019-07-02Grunenthal GmbhTamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en)2013-11-262019-10-22Grünenthal GmbHPreparation of a powdery pharmaceutical composition by means of cryo-milling
US10624862B2 (en)2013-07-122020-04-21Grünenthal GmbHTamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10695297B2 (en)2011-07-292020-06-30Grünenthal GmbHTamper-resistant tablet providing immediate drug release
US10729658B2 (en)2005-02-042020-08-04Grünenthal GmbHProcess for the production of an abuse-proofed dosage form
US10842750B2 (en)2015-09-102020-11-24Grünenthal GmbHProtecting oral overdose with abuse deterrent immediate release formulations
US11224576B2 (en)2003-12-242022-01-18Grünenthal GmbHProcess for the production of an abuse-proofed dosage form
US11478426B2 (en)2018-09-252022-10-25SpecGx LLCAbuse deterrent immediate release capsule dosage forms
US11517521B2 (en)2014-07-032022-12-06SpecGx LLCAbuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US11844865B2 (en)2004-07-012023-12-19Grünenthal GmbHAbuse-proofed oral dosage form

Families Citing this family (141)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
JP2005520778A (en)*2001-07-062005-07-14エンドー ファーマシューティカルズ, インコーポレイティド Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
ES2292775T3 (en)*2001-07-062008-03-16Penwest Pharmaceuticals Co. FORMULATIONS OF PROLONGED RELEASE OF OXIMORPHONE.
US8329216B2 (en)*2001-07-062012-12-11Endo Pharmaceuticals Inc.Oxymorphone controlled release formulations
US7157103B2 (en)2001-08-062007-01-02Euro-Celtique S.A.Pharmaceutical formulation containing irritant
WO2003015531A2 (en)*2001-08-062003-02-27Thomas GruberPharmaceutical formulation containing dye
US20030068375A1 (en)2001-08-062003-04-10Curtis WrightPharmaceutical formulation containing gelling agent
US7842307B2 (en)*2001-08-062010-11-30Purdue Pharma L.P.Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
EP1429730A4 (en)*2001-09-262010-06-16Penwest Pharmaceuticals CompanOpioid formulations having reduced potential for abuse
CA2464528A1 (en)*2001-11-022003-05-15Elan Corporation, PlcPharmaceutical composition
US8128957B1 (en)2002-02-212012-03-06Valeant International (Barbados) SrlModified release compositions of at least one form of tramadol
US20050182056A9 (en)*2002-02-212005-08-18Seth PawanModified release formulations of at least one form of tramadol
US20040109886A1 (en)*2002-08-272004-06-10Larry RigbyMethods and apparatus for transdermal delivery of abusable drugs with a deterrent agent
CN1703200B (en)2002-09-202012-02-29奥尔制药公司Sequestering subunit and related compositions and methods
WO2004026262A2 (en)*2002-09-232004-04-01Verion, Inc.Abuse-resistant pharmaceutical compositions
US7524515B2 (en)*2003-01-102009-04-28Mutual Pharmaceuticals, Inc.Pharmaceutical safety dosage forms
US20040202717A1 (en)*2003-04-082004-10-14Mehta Atul M.Abuse-resistant oral dosage forms and method of use thereof
DE102004020220A1 (en)*2004-04-222005-11-10Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
BRPI0413361B8 (en)*2003-08-062021-05-25Gruenenthal Gmbh abuse-safe tablet thermoformed by non-bleaching extrusion
US7201920B2 (en)*2003-11-262007-04-10Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of opioid containing dosage forms
SI1765292T1 (en)2004-06-122018-04-30Collegium Pharmaceutical, Inc.Abuse-deterrent drug formulations
DE102004032103A1 (en)*2004-07-012006-01-19Grünenthal GmbH Anti-abuse, oral dosage form
US20060051298A1 (en)*2004-09-032006-03-09Groenewoud Pieter JAbuse resistent pharmaceutical dosage and method of making same
CN101031322A (en)*2004-10-012007-09-05日本脏器制药株式会社Solid pharmaceutical preparation
US20060177380A1 (en)*2004-11-242006-08-10Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en)*2004-11-242006-05-25Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en)*2004-11-242008-06-26Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20070231268A1 (en)*2004-11-242007-10-04Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
WO2006103551A1 (en)*2005-03-312006-10-05Ranbaxy Laboratories LimitedControlled release formulations of oxycodone
WO2007048220A2 (en)*2005-09-092007-05-03Labopharm Inc.Trazodone composition for once a day adminisitiation
ES2620293T3 (en)*2005-09-092017-06-28Paladin Labs Inc. Sustained drug release composition
US8852638B2 (en)2005-09-302014-10-07Durect CorporationSustained release small molecule drug formulation
EP3132792B1 (en)2005-11-222019-09-11Nalpropion Pharmaceuticals, Inc.Composition and methods for increasing insulin sensitivity
US20090022798A1 (en)*2007-07-202009-01-22Abbott Gmbh & Co. KgFormulations of nonopioid and confined opioid analgesics
US20100172989A1 (en)*2006-01-212010-07-08Abbott LaboratoriesAbuse resistant melt extruded formulation having reduced alcohol interaction
US20090317355A1 (en)*2006-01-212009-12-24Abbott Gmbh & Co. Kg,Abuse resistant melt extruded formulation having reduced alcohol interaction
US20070212414A1 (en)*2006-03-082007-09-13Penwest Pharmaceuticals Co.Ethanol-resistant sustained release formulations
WO2007114376A1 (en)*2006-03-302007-10-11Nippon Zoki Pharmaceutical Co., Ltd.Solid pharmaceutical preparation
US8916195B2 (en)2006-06-052014-12-23Orexigen Therapeutics, Inc.Sustained release formulation of naltrexone
US20070281016A1 (en)*2006-06-062007-12-06Endo Pharmaceuticals Inc., A Delaware CorporationSustained release oxycodone composition with acrylic polymer and surfactant
PT2526932T (en)2006-06-192017-08-10Alpharma Pharmaceuticals LlcPharmaceutical composition
US8765178B2 (en)*2006-07-192014-07-01Watson Laboratories, Inc.Controlled release formulations and associated methods
AU2007275034A1 (en)*2006-07-212008-01-24Lab International SrlHydrophilic abuse deterrent delivery system
AU2013201019B2 (en)*2006-08-252015-04-09Purdue Pharma LpTamper resistant oral pharmaceutical dosage forms comprising an opioid analgesic
EP1897543A1 (en)2006-08-302008-03-12Euro-Celtique S.A.Buprenorphine- wafer for drug substitution therapy
US8445018B2 (en)2006-09-152013-05-21Cima Labs Inc.Abuse resistant drug formulation
EP2124556B1 (en)2006-10-092014-09-03Charleston Laboratories, Inc.Pharmaceutical compositions
JP2010506833A (en)*2006-10-112010-03-04アルファーマ,インコーポレイテッド Pharmaceutical composition
KR20090090316A (en)2006-11-092009-08-25오렉시젠 세러퓨틱스 인크. Unit dose packages and methods of administration for administering weight loss drugs
AU2008262545B2 (en)2007-05-252013-12-05Indivior Uk LimitedSustained delivery formulations of risperidone compounds
EP2167049B1 (en)*2007-06-042016-08-31Shear/Kershman Laboratories, Inc.Tamper resistant lipid-based oral dosage form for opioid agonists
US20090124650A1 (en)*2007-06-212009-05-14Endo Pharmaceuticals, Inc.Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
JP5965583B2 (en)2007-08-132016-08-10インスピリオン デリバリー テクノロジーズ エルエルシー Abuse resistant pharmaceutical composition, method of use and preparation
US8623418B2 (en)2007-12-172014-01-07Alpharma Pharmaceuticals LlcPharmaceutical composition
US20100151014A1 (en)*2008-12-162010-06-17Alpharma Pharmaceuticals, LlcPharmaceutical composition
US20090196890A1 (en)*2007-12-172009-08-06Alpharma Pharmaceuticals, LlcPharmaceutical compositions
MX2010006694A (en)2007-12-172010-09-07Labopharm IncMisuse preventative, controlled release formulation.
EP3090743A1 (en)2008-01-092016-11-09Charleston Laboratories, Inc.Pharmaceutical compositions for treating headache and eliminating nausea
JP2011511782A (en)2008-02-122011-04-14アボット・ラボラトリーズ Extended release hydrocodone acetaminophen and related methods and uses
US20090325999A1 (en)*2008-06-272009-12-31Jie DuPersonalized pharmaceutical kits, packaging and compositions for the treatment of allergic conditions
US8460640B2 (en)*2008-12-122013-06-11Paladin Labs, Inc.Narcotic drug formulations with decreased abuse potential
WO2010069050A1 (en)2008-12-162010-06-24Labopharm Inc.Misuse preventative, controlled release formulation
US8362029B2 (en)2008-12-312013-01-29Upsher-Smith Laboratories, Inc.Opioid-containing oral pharmaceutical compositions and methods
DK3045043T3 (en)*2009-02-262020-08-03Relmada Therapeutics Inc ORAL PHARMACEUTICAL COMPOSITIONS OF 3-HYDROXY-N-METHYLMORPHINANE WITH EXTENDED RELEASE AND METHOD OF USE
GB0909680D0 (en)*2009-06-052009-07-22Euro Celtique SaDosage form
US8263581B2 (en)2009-07-032012-09-11Jdp Therapeutics, Inc.Non-sedating antihistamine injection formulations and methods of use thereof
US8513259B2 (en)2009-07-032013-08-20Jdp Therapeutics, Inc.Non-sedating antihistamine injection formulations and methods of use thereof
CA2767576C (en)2009-07-082020-03-10Charleston Laboratories Inc.Pharmaceutical compositions comprising an antiemetic and an opioid analgesic
WO2011034554A1 (en)2009-09-172011-03-24Upsher-Smith Laboratories, Inc.A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug
US8901113B2 (en)2009-09-302014-12-02Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse
US10668060B2 (en)2009-12-102020-06-02Collegium Pharmaceutical, Inc.Tamper-resistant pharmaceutical compositions of opioids and other drugs
CN102665694A (en)*2009-12-172012-09-12思玛化验室公司Abuse-resistant formulations
RU2616496C2 (en)2010-01-112017-04-17Ориксиджен Терапьютикс, Инк.Methods of weight loss therapy in patients with dominant depression (versions)
US9272044B2 (en)2010-06-082016-03-01Indivior Uk LimitedInjectable flowable composition buprenorphine
GB2481017B (en)2010-06-082015-01-07Rb Pharmaceuticals LtdMicroparticle buprenorphine suspension
AP3815A (en)2010-12-222016-09-30Purdue Pharma LpEncased tamper resistant controlled release dosage forms
PH12013501345A1 (en)2010-12-232022-10-24Purdue Pharma LpTamper resistant solid oral dosage forms
EP2675436A1 (en)*2011-02-172013-12-25Qrxpharma LimitedTechnology for preventing abuse of solid dosage forms
US20140341984A1 (en)*2011-09-162014-11-20Purdue Pharma L.P.Tamper resistant pharmaceutical formulations
US8940330B2 (en)2011-09-192015-01-27Orexo AbAbuse-resistant pharmaceutical composition for the treatment of opioid dependence
WO2013077851A1 (en)*2011-11-222013-05-30Watson Pharmaceuticals, Inc.Immediate release abuse deterrent tablet
EA028224B1 (en)2012-03-022017-10-31Роудс Фармасьютикалз Л.П.Tamper resistant immediate release formulations
IN2014DN09238A (en)2012-04-172015-07-10Purdue Pharma Lp
CA2875056C (en)2012-06-062024-03-26Orexigen Therapeutics, Inc.Methods of treating overweight and obesity
CA2791206A1 (en)*2012-09-282014-03-28Pharmascience Inc.Abuse deterrent pharmaceutical formulation
CN107595793B (en)2012-11-302020-11-13阿库拉制药公司 Self-regulating release of active pharmaceutical ingredients
FR2999426B1 (en)2012-12-132015-01-02Flamel Tech Sa MULTIPARTICULAR ORAL FORM WITH IMMEDIATE RELEASE OF AT LEAST ONE ACTIVE COMPOUND, INCLUDING MILL RESISTANT MIXED PARTICLES.
EA201500742A1 (en)2013-02-052015-12-30Пердью Фарма Л.П. PHARMACEUTICAL COMPOSITIONS PROTECTED FROM NON-GOAL USE
US9517208B2 (en)2013-03-152016-12-13Purdue Pharma L.P.Abuse-deterrent dosage forms
US10751287B2 (en)2013-03-152020-08-25Purdue Pharma L.P.Tamper resistant pharmaceutical formulations
CA2907428A1 (en)2013-03-152014-09-18Inspirion Delivery Technologies, LlcAbuse deterrent compositions and methods of use
WO2015023675A2 (en)2013-08-122015-02-19Pharmaceutical Manufacturing Research Services, Inc.Extruded immediate release abuse deterrent pill
US9770514B2 (en)2013-09-032017-09-26ExxPharma Therapeutics LLCTamper-resistant pharmaceutical dosage forms
US20150118300A1 (en)2013-10-312015-04-30Cima Labs Inc.Immediate Release Abuse-Deterrent Granulated Dosage Forms
US8969371B1 (en)2013-12-062015-03-03Orexigen Therapeutics, Inc.Compositions and methods for weight loss in at risk patient populations
US9492444B2 (en)2013-12-172016-11-15Pharmaceutical Manufacturing Research Services, Inc.Extruded extended release abuse deterrent pill
WO2015095391A1 (en)*2013-12-172015-06-25Pharmaceutical Manufacturing Research Services, Inc.Extruded extended release abuse deterrent pill
WO2015120201A1 (en)2014-02-052015-08-13Kashiv Pharma, LlcAbuse-resistant drug formulations with built-in overdose protection
GB201404139D0 (en)2014-03-102014-04-23Rb Pharmaceuticals LtdSustained release buprenorphine solution formulations
AU2015237721B2 (en)2014-03-262018-04-26Sun Pharma Advanced Research Company Ltd.Abuse deterrent immediate release coated reservoir solid dosage form
JP6371463B2 (en)2014-07-172018-08-08ファーマシューティカル マニュファクチュアリング リサーチ サービシズ,インコーポレーテッド Immediate release abuse deterrent liquid filler form
US9132096B1 (en)2014-09-122015-09-15Alkermes Pharma Ireland LimitedAbuse resistant pharmaceutical compositions
US10729685B2 (en)2014-09-152020-08-04Ohemo Life Sciences Inc.Orally administrable compositions and methods of deterring abuse by intranasal administration
US9849124B2 (en)2014-10-172017-12-26Purdue Pharma L.P.Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CA2964628A1 (en)2014-10-202016-04-28Pharmaceutical Manufacturing Research Services, Inc.Extended release abuse deterrent liquid fill dosage form
WO2016094358A1 (en)*2014-12-082016-06-16Cima Labs Inc.Immediate release abuse-deterrent granulated dosage forms
EA201792014A1 (en)2015-03-102018-01-31Родс Текнолоджис ACETATE SALT BUPRENORPHINE AND METHODS FOR OBTAINING BUPRENORPHINE
JP6784596B2 (en)2015-06-302020-11-11第一三共株式会社 Pharmaceutical composition with abuse prevention function
US20170017683A1 (en)*2015-07-132017-01-1928msecSystems And Methods For Storing And Interacting With Data From Heterogeneous Data Sources
HUE052500T2 (en)*2015-08-112021-04-28Unilever NvWater-soluble package
BR112018002491B1 (en)*2015-08-112022-06-07Unilever Ip Holdings B.V. Water-soluble packaging, method of producing a water-soluble packaging and using a water-soluble packaging
WO2017040607A1 (en)2015-08-312017-03-09Acura Pharmaceuticals, Inc.Methods and compositions for self-regulated release of active pharmaceutical ingredient
US9943513B1 (en)2015-10-072018-04-17Banner Life Sciences LlcOpioid abuse deterrent dosage forms
US20180303757A1 (en)2015-10-232018-10-25Kashiv Pharma LlcEnhanced abuse-deterrent formulations of oxycodone
EP3413893A4 (en)2016-02-082019-08-28SpecGx LLCGlucomannan containing pharmaceutical compositions with extended release and abuse deterrent properties
DE102016002508A1 (en)*2016-03-012017-09-07Giesecke+Devrient Mobile Security Gmbh A method for loading a subscription into an embedded security element of a mobile terminal
JP2019507783A (en)*2016-03-092019-03-22エムダブリュ エンキャップ リミテッド Abuse prevention pharmaceutical preparation
US10683395B2 (en)*2016-04-072020-06-16Basf SeDual-curable sealant composition
EP3440147A1 (en)*2016-04-072019-02-13Basf SeCurable sealant composition
US10335405B1 (en)2016-05-042019-07-02Patheon Softgels, Inc.Non-burst releasing pharmaceutical composition
WO2017222575A1 (en)2016-06-232017-12-28Collegium Pharmaceutical, Inc.Process of making more stable abuse-deterrent oral formulations
US10287366B2 (en)2017-02-152019-05-14Cp Kelco ApsMethods of producing activated pectin-containing biomass compositions
US20180250287A1 (en)*2017-03-062018-09-06Tactus Therapeutics, Inc.Abuse deterrent opioid formulations
CA3068036A1 (en)2017-06-302019-01-03Purdue Pharma L.P.Use to buprenorphine in combination with an opioid to treat pain
US11510877B2 (en)*2017-10-102022-11-29Capsugel Belgium NvGelling multiparticulates
CN111212895A (en)2017-10-132020-05-29荷兰联合利华有限公司Aqueous spray composition
CN111971375A (en)2017-10-132020-11-20荷兰联合利华有限公司Fabric spray compositions
CN111212894A (en)2017-10-132020-05-29荷兰联合利华有限公司Aqueous spray composition
US11649416B2 (en)2017-10-132023-05-16Conopco, Inc.Aqueous spray composition comprising silicone and perfume microemulsions
EP3473246A1 (en)2017-10-192019-04-24Capsugel Belgium NVImmediate release abuse deterrent formulations
MX2020005438A (en)*2017-12-202020-12-03Purdue Pharma LpAbuse deterrent morphine sulfate dosage forms.
US20210322321A1 (en)*2018-10-192021-10-21Temple University-Of The Commonwealth System Of Higher EducationTamper-resistant drug dosage forms and methods of making and use thereof
EP3946547A4 (en)2019-03-262023-01-18Pocket Naloxone Corp.Devices and methods for delivering pharmaceutical compositions
US20220062200A1 (en)2019-05-072022-03-03Clexio Biosciences Ltd.Abuse-deterrent dosage forms containing esketamine
EP3965733A4 (en)2019-05-072023-01-11Clexio Biosciences Ltd.Abuse-deterrent dosage forms containing esketamine
CN113825502A (en)*2019-05-072021-12-21澳谛医药科技有限公司Materials and methods for treating drug-induced gingival hyperplasia
US11701350B2 (en)*2019-07-222023-07-18L. Perrigo CompanyDextromethorphan extended release pharmaceutical composition
EP4117629A4 (en)*2020-03-112023-08-30Purdue Pharma L.P.Compositions and methods for naloxone delivery
EP4171228A4 (en)*2020-06-262024-07-31Sensient Colors LLCEnteric coating composition and method of making and using the same
US11278709B1 (en)2021-03-122022-03-22Pocket Naloxone Corp.Drug delivery device and methods for using same
KR20220149828A (en)2021-04-302022-11-09삼성전자주식회사Semiconductor devices
JP2024526839A (en)*2021-07-202024-07-19ピナクル バイオロジクス,インコーポレイテッド Photodynamic therapy compositions and methods of treatment therewith

Citations (92)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3133132A (en)*1960-11-291964-05-12Univ CaliforniaHigh flow porous membranes for separating water from saline solutions
US3173876A (en)*1960-05-271965-03-16John C ZobristCleaning methods and compositions
US3260646A (en)*1962-10-191966-07-12Ferring AbMedication with mechanism to prevent overdosage
US3276586A (en)*1963-08-301966-10-04Rosaen Filter CoIndicating means for fluid filters
US3980766A (en)*1973-08-131976-09-14West Laboratories, Inc.Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4070494A (en)*1975-07-091978-01-24Bayer AktiengesellschaftEnteral pharmaceutical compositions
US4088864A (en)*1974-11-181978-05-09Alza CorporationProcess for forming outlet passageways in pills using a laser
US4160020A (en)*1975-11-241979-07-03Alza CorporationTherapeutic device for osmotically dosing at controlled rate
US4200098A (en)*1978-10-231980-04-29Alza CorporationOsmotic system with distribution zone for dispensing beneficial agent
US4285987A (en)*1978-10-231981-08-25Alza CorporationProcess for manufacturing device with dispersion zone
US4293539A (en)*1979-09-121981-10-06Eli Lilly And CompanyControlled release formulations and method of treatment
US4385057A (en)*1978-10-201983-05-24Ab FerrosanDiphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods
US4389393A (en)*1982-03-261983-06-21Forest Laboratories, Inc.Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4424205A (en)*1982-03-181984-01-03The Procter & Gamble CompanyHydroxyphenylacetamides having analgesic and anti-irritant activity
US4457933A (en)*1980-01-241984-07-03Bristol-Myers CompanyPrevention of analgesic abuse
US4459278A (en)*1983-03-071984-07-10Clear Lake Development GroupComposition and method of immobilizing emetics and method of treating human beings with emetics
US4588580A (en)*1984-07-231986-05-13Alza CorporationTransdermal administration of fentanyl and device therefor
US4599342A (en)*1984-01-161986-07-08The Procter & Gamble CompanyPharmaceutical products providing enhanced analgesia
US4610870A (en)*1984-10-051986-09-09E. R. Squibb & Sons, Inc.Controlled release formulation
US4666705A (en)*1985-06-031987-05-19E. R. Squibb & Sons, Inc.Controlled release formulation
US4769372A (en)*1986-06-181988-09-06The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4806341A (en)*1985-02-251989-02-21Rutgers, The State University Of New JerseyTransdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4812446A (en)*1984-01-161989-03-14The Procter & Gamble CompanyPharmaceutical products providing enhanced analgesia
US4861598A (en)*1986-07-181989-08-29Euroceltique, S.A.Controlled release bases for pharmaceuticals
US4957681A (en)*1988-04-151990-09-18Basf AktiengesellschaftPreparation of pharmaceutical mixtures
US4990341A (en)*1986-10-311991-02-05Euroceltique, S.A.Controlled release hydromorphone composition
US5026556A (en)*1988-11-101991-06-25Norwich Eaton Pharmaceuticals, Inc.Compositions for the transdermal delivery of pharmaceutical actives
US5059600A (en)*1989-03-311991-10-22Yale UniversityTreating habit disorders
US5111942A (en)*1990-04-251992-05-12Didier BernardinDisplay tray for aligned articles
US5114942A (en)*1989-03-311992-05-19Yale UniversityTreating habit disorders
US5130311A (en)*1990-11-201992-07-14Adir Et CompagnieOxazolopyridine compounds, compositions and use
US5149538A (en)*1991-06-141992-09-22Warner-Lambert CompanyMisuse-resistive transdermal opioid dosage form
US5215758A (en)*1991-09-111993-06-01Euroceltique, S.A.Controlled release matrix suppository for pharmaceuticals
US5225199A (en)*1990-04-241993-07-06Teijin LimitedPharmaceutical plasters
US5240711A (en)*1989-11-291993-08-31Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system comprising as active component buprenorphine
US5286493A (en)*1992-01-271994-02-15Euroceltique, S.A.Stabilized controlled release formulations having acrylic polymer coating
US5290816A (en)*1988-10-241994-03-01The United States Of America As Represented By The Secretary Of Health And Human ServicesComposition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization
US5321012A (en)*1993-01-281994-06-14Virginia Commonwealth University Medical CollegeInhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5324351A (en)*1992-08-131994-06-28EuroceltiqueAqueous dispersions of zein and preparation thereof
US5330766A (en)*1989-01-061994-07-19F. H. Faulding & Co. LimitedSustained release pharmaceutical composition
US5403868A (en)*1988-12-231995-04-04Sandoz Ltd.Capsaicin derivatives
US5409944A (en)*1993-03-121995-04-25Merck Frosst Canada, Inc.Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5436265A (en)*1993-11-121995-07-25Merck Frosst Canada, Inc.1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5500227A (en)*1993-11-231996-03-19Euro-Celtique, S.A.Immediate release tablet cores of insoluble drugs having sustained-release coating
US5502058A (en)*1993-03-051996-03-26Virginia Commonwealth UniversityMethod for the treatment of pain
US5510368A (en)*1995-05-221996-04-23Merck Frosst Canada, Inc.N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5514680A (en)*1992-06-221996-05-07The State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityGlycine receptor antagonists and the use thereof
US5521213A (en)*1994-08-291996-05-28Merck Frosst Canada, Inc.Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5536752A (en)*1993-06-241996-07-16Merck Frosst Canada Inc.Phenyl heterocycles as COX-2 inhibitors
US5552422A (en)*1995-01-111996-09-03Merck Frosst Canada, Inc.Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5593994A (en)*1994-09-291997-01-14The Dupont Merck Pharmaceutical CompanyProstaglandin synthase inhibitors
US5604260A (en)*1992-12-111997-02-18Merck Frosst Canada Inc.5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5604253A (en)*1995-05-221997-02-18Merck Frosst Canada, Inc.N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5616601A (en)*1994-07-281997-04-01Gd Searle & Co1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5639780A (en)*1995-05-221997-06-17Merck Frosst Canada, Inc.N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5639476A (en)*1992-01-271997-06-17Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5672360A (en)*1993-11-231997-09-30Purdue Pharma, L.P.Method of treating pain by administering 24 hour oral opioid formulations
US5741524A (en)*1995-01-091998-04-21Edward Mendell Co., Inc.Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US5762963A (en)*1995-06-071998-06-09Emory UniversityMethod and compositions for controlling oral and pharyngeal pain using capsaicinoids
US5891919A (en)*1997-09-191999-04-06Burlington Bio-Medical & Scientific Corp.Denatonium capsaicinate and methods of producing the same
US6228863B1 (en)*1997-12-222001-05-08Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6277398B1 (en)*1997-05-272001-08-21Endo Pharmaceuticals Inc.Analgesic drug composition containing a capsaicinoid and potentiator therefor
US6352721B1 (en)*2000-01-142002-03-05Osmotica Corp.Combined diffusion/osmotic pumping drug delivery system
US6375957B1 (en)*1997-12-222002-04-23Euro-Celtique, S.A.Opioid agonist/opioid antagonist/acetaminophen combinations
US6440464B1 (en)*1996-06-102002-08-27Viva Life ScienceNutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US20030004177A1 (en)*2001-05-112003-01-02Endo Pharmaceuticals, Inc.Abuse-resistant opioid dosage form
US20030026838A1 (en)*2001-06-262003-02-06Farrell John J.Tamper-proof narcotic delivery system
US20030059471A1 (en)*1997-12-152003-03-27Compton Bruce JonOral delivery formulation
US20030064099A1 (en)*2001-08-062003-04-03Benjamin OshlackPharmaceutical formulation containing bittering agent
US20030064122A1 (en)*2001-05-232003-04-03Endo Pharmaceuticals, Inc.Abuse resistant pharmaceutical composition containing capsaicin
US20030068370A1 (en)*2001-08-062003-04-10Richard SacklerPharmaceutical formulation containing irritant
US20030068392A1 (en)*2001-08-062003-04-10Richard SacklerPharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068375A1 (en)*2001-08-062003-04-10Curtis WrightPharmaceutical formulation containing gelling agent
US20030068276A1 (en)*2001-09-172003-04-10Lyn HughesDosage forms
US6559159B2 (en)*2001-02-012003-05-06Research Triangle InstituteKappa opioid receptor ligands
US6572885B2 (en)*1991-12-242003-06-03Euro-Celtique, S.A.Orally administrable opioid formulations having extended duration of effect
US20030125347A1 (en)*2001-11-022003-07-03Elan Corporation PlcPharmaceutical composition
US20030124061A1 (en)*2003-01-102003-07-03Roberts Richard H.Pharmaceutical safety dosage forms
US20030124185A1 (en)*2001-08-062003-07-03Benjamin OshlackPharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030126428A1 (en)*2001-12-282003-07-03Liu Fang-ChengLifm algorithm for security association database lookup in IPSEC application
US6593367B1 (en)*1998-08-052003-07-15Brookhaven Science AssociatesTreatment of addiction and addiction-related behavior
US20030170181A1 (en)*1999-04-062003-09-11Midha Kamal K.Method for preventing abuse of methylphenidate
US6696088B2 (en)*2000-02-082004-02-24Euro-Celtique, S.A.Tamper-resistant oral opioid agonist formulations
US20040131552A1 (en)*2002-09-202004-07-08Alpharma, Inc.Sequestering subunit and related compositions and methods
US20040151791A1 (en)*2002-11-152004-08-05Ricardo Mayo-AlvarezPharmaceutical composition
US20050020613A1 (en)*2002-09-202005-01-27Alpharma, Inc.Sustained release opioid formulations and method of use
US20050063909A1 (en)*2001-08-062005-03-24Euro-Celtique, S.A.Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20050106249A1 (en)*2002-04-292005-05-19Stephen HwangOnce-a-day, oral, controlled-release, oxycodone dosage forms
US20050112067A1 (en)*2003-11-262005-05-26Vijai KumarMethods and compositions for deterring abuse of opioid containing dosage forms
US20050163717A1 (en)*2004-01-232005-07-28Birch Point Medical, Inc.Abuse potential reduction in abusable substance dosage form
US20050214223A1 (en)*2002-10-252005-09-29Gruenenthal GmbhAbuse-safeguarded dosage form
US20060018837A1 (en)*2004-07-262006-01-26Victory Pharma, Inc.Pharmaceutical compositions and methods for the prevention of drug misuse

Family Cites Families (197)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3065143A (en)*1960-04-191962-11-20Richardson Merrell IncSustained release tablet
US3260846A (en)1963-04-091966-07-12Canrad Prec Ind IncBeta ray light source structure
US4132753A (en)*1965-02-121979-01-02American Cyanamid CompanyProcess for preparing oral sustained release granules
NL6714885A (en)1967-11-021969-05-06
US3541006A (en)1968-07-031970-11-17Amicon CorpUltrafiltration process
US3541005A (en)1969-02-051970-11-17Amicon CorpContinuous ultrafiltration of macromolecular solutions
US3980776A (en)1969-05-261976-09-14Nakao IshidaComposition containing double stranded RNA from basidiomycetes and method of use
US3879555A (en)1970-11-161975-04-22Bristol Myers CoMethod of treating drug addicts
GB1405088A (en)1971-06-031975-09-03Mundipharma AgSlow release formulation
US3965256A (en)1972-05-161976-06-22SynergisticsSlow release pharmaceutical compositions
US3845770A (en)1972-06-051974-11-05Alza CorpOsmatic dispensing device for releasing beneficial agent
US3916889A (en)1973-09-281975-11-04Sandoz AgPatient ventilator apparatus
US4063064A (en)1976-02-231977-12-13Coherent RadiationApparatus for tracking moving workpiece by a laser beam
US4175119A (en)*1978-01-111979-11-20Porter Garry LComposition and method to prevent accidental and intentional overdosage with psychoactive drugs
CA1146866A (en)1979-07-051983-05-24Yamanouchi Pharmaceutical Co. Ltd.Process for the production of sustained release pharmaceutical composition of solid medical material
IE49324B1 (en)1979-12-191985-09-18Euro Celtique SaControlled release compositions
US4443428A (en)1982-06-211984-04-17Euroceltique, S.A.Extended action controlled release compositions
US4765989A (en)1983-05-111988-08-23Alza CorporationOsmotic device for administering certain drugs
US4612008A (en)1983-05-111986-09-16Alza CorporationOsmotic device with dual thermodynamic activity
US4629623A (en)1984-06-111986-12-16Biomatrix, Inc.Hyaluronate-poly (ethylene oxide) compositions and cosmetic formulations thereof
US4629621A (en)1984-07-231986-12-16Zetachron, Inc.Erodible matrix for sustained release bioactive composition
GB8430346D0 (en)*1984-11-301985-01-09Reckitt & Colmann Prod LtdAnalgesic compositions
US4797286A (en)*1985-11-121989-01-10Eli Lilly And CompanyOrally administerable sustained release pharmaceutical formulations
US4971790A (en)1986-02-071990-11-20Alza CorporationDosage form for lessening irritation of mocusa
US4764378A (en)1986-02-101988-08-16Zetachron, Inc.Buccal drug dosage form
EP0249347B1 (en)1986-06-101994-06-29Euroceltique S.A.Controlled release dihydrocodeine composition
US4785000A (en)1986-06-181988-11-15The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4970075A (en)1986-07-181990-11-13Euroceltique, S.A.Controlled release bases for pharmaceuticals
US4737151A (en)1986-07-251988-04-12Clement John GSyringe injector
US4710384A (en)1986-07-281987-12-01Avner RotmanSustained release tablets made from microcapsules
GB8727504D0 (en)1987-11-241987-12-23Glaxo Group LtdChemical compositions
GB8728294D0 (en)1987-12-031988-01-06Reckitt & Colmann Prod LtdTreatment compositions
US5139790A (en)*1988-10-141992-08-18Zetachron, Inc.Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
US5202128A (en)1989-01-061993-04-13F. H. Faulding & Co. LimitedSustained release pharmaceutical composition
US4992277A (en)1989-08-251991-02-12Schering CorporationImmediate release diltiazem formulation
EP0418596A3 (en)1989-09-211991-10-23American Cyanamid CompanyControlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5169645A (en)1989-10-311992-12-08Duquesne University Of The Holy GhostDirectly compressible granules having improved flow properties
DE3937118A1 (en)1989-11-031991-05-08Schering Ag NON-ionic x-ray contrast agents with high iodine content
US5232685A (en)1989-11-031993-08-03Schering AktiengesellschaftNonionic x-ray contrast medium with high iodine content
GB8926612D0 (en)1989-11-241990-01-17Erba FarmitaliaPharmaceutical compositions
IT1237904B (en)1989-12-141993-06-18Ubaldo Conte CONTROLLED SPEED RELEASE TABS OF ACTIVE SUBSTANCES
US5679650A (en)*1993-11-241997-10-21Fukunaga; Atsuo F.Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5069909A (en)1990-06-201991-12-03Cygnus Therapeutic SystemsTransdermal administration of buprenorphine
US5246698A (en)1990-07-091993-09-21Biomatrix, Inc.Biocompatible viscoelastic gel slurries, their preparation and use
US6096722A (en)1990-08-142000-08-01Isis Pharmaceuticals Inc.Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases
US5113585A (en)1990-09-281992-05-19The Gillette CompanyShaving system
US5300302A (en)1990-10-041994-04-05Nestec S.A.Pharmaceutical composition in gel form in a dispensing package
SE9003904D0 (en)1990-12-071990-12-07Astra Ab METHOD FOR THE MANUFACTURE OF A PHARMACEUTICAL DOSAGE FORM
US5273758A (en)1991-03-181993-12-28Sandoz Ltd.Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
WO1993006166A1 (en)*1991-09-181993-04-01Transcontinental Marketing Group Inc.One coat protective system for a surface
US5656295A (en)*1991-11-271997-08-12Euro-Celtique, S.A.Controlled release oxycodone compositions
US5266331A (en)1991-11-271993-11-30Euroceltique, S.A.Controlled release oxycodone compositions
US5958459A (en)1991-12-241999-09-28Purdue Pharma L.P.Opioid formulations having extended controlled released
US5472712A (en)1991-12-241995-12-05Euroceltique, S.A.Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5273760A (en)1991-12-241993-12-28Euroceltigue, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5681585A (en)1991-12-241997-10-28Euro-Celtique, S.A.Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5354863A (en)1992-01-211994-10-11G. D. Searle & Co.Opioid agonist compounds
US5237760A (en)1992-03-091993-08-24Peter R. AltmanElectrically lighted footwear
US5582837A (en)1992-03-251996-12-10Depomed, Inc.Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
AU658271B2 (en)1992-03-261995-04-06Tanabe Seiyaku Co., Ltd.Butadiene derivatives and process for preparing the same
JP3278192B2 (en)1992-04-032002-04-30ロート製薬株式会社 Sustained release liquid
US5232934A (en)1992-07-171993-08-03Warner-Lambert Co.Method for the treatment of psychomotor stimulant addiction
JP3140465B2 (en)1992-09-182001-03-05山之内製薬株式会社 Hydrogel sustained release formulation
US5472943A (en)1992-09-211995-12-05Albert Einstein College Of Medicine Of Yeshiva University,Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists
GB9226392D0 (en)1992-12-181993-02-10Cpc International IncGelling agent
US5376384A (en)1992-12-231994-12-27Kinaform Technology, Inc.Delayed, sustained-release pharmaceutical preparation
IL110014A (en)1993-07-011999-11-30Euro Celtique SaSolid controlled-release oral dosage forms of opioid analgesics
US5879705A (en)1993-07-271999-03-09Euro-Celtique S.A.Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
KR100354702B1 (en)1993-11-232002-12-28유로-셀티크 소시에떼 아노뉨 Manufacturing method and sustained release composition of pharmaceutical composition
US5891471A (en)1993-11-231999-04-06Euro-Celtique, S.A.Pharmaceutical multiparticulates
US6210714B1 (en)1993-11-232001-04-03Euro-Celtique S.A.Immediate release tablet cores of acetaminophen having sustained-release coating
WO1995018602A1 (en)1994-01-111995-07-13Alkermes Controlled Therapeutics, Inc.ORAL DOSAGE FORM OF DESMOPRESSIN (dDAVP)
GB9401894D0 (en)*1994-02-011994-03-30Rhone Poulenc Rorer LtdNew compositions of matter
US5843480A (en)1994-03-141998-12-01Euro-Celtique, S.A.Controlled release diamorphine formulation
US5411745A (en)1994-05-251995-05-02Euro-Celtique, S.A.Powder-layered morphine sulfate formulations
US5460826A (en)1994-06-271995-10-24Alza CorporationMorphine therapy
US5529787A (en)1994-07-071996-06-25Alza CorporationHydromorphone therapy
US5914131A (en)1994-07-071999-06-22Alza CorporationHydromorphone therapy
WO1996005884A1 (en)1994-08-221996-02-29Iomed, Inc.Iontophoretic delivery device with integral hydrating means
US5575993A (en)1994-08-311996-11-19Buckman Laboratories International, Inc.Ionene polymers containing biologically-active anions
US5516808A (en)1994-10-271996-05-14Sawaya; Assad S.Topical cellulose pharmaceutical formulation
US5965161A (en)1994-11-041999-10-12Euro-Celtique, S.A.Extruded multi-particulates
US5545628A (en)*1995-01-101996-08-13Galephar P.R. Inc.Pharmaceutical composition containing fenofibrate
US5945125A (en)1995-02-281999-08-31Temple UniversityControlled release tablet
US5695781A (en)*1995-03-011997-12-09Hallmark Pharmaceuticals, Inc.Sustained release formulation containing three different types of polymers
US6348469B1 (en)*1995-04-142002-02-19Pharma Pass LlcSolid compositions containing glipizide and polyethylene oxide
US5643992A (en)1995-06-021997-07-01Minnesota Mining And Manufacturing CompanyCoating additives for water-based formulations
US5747058A (en)1995-06-071998-05-05Southern Biosystems, Inc.High viscosity liquid controlled delivery system
EP0840610A1 (en)*1995-07-141998-05-13Medeva Europe LimitedComposition comprising d-threo-methylphenidate and another drug
GB9514451D0 (en)*1995-07-141995-09-13Chiroscience LtdSustained-release formulation
US5811126A (en)1995-10-021998-09-22Euro-Celtique, S.A.Controlled release matrix for pharmaceuticals
AUPN605795A0 (en)*1995-10-191995-11-09F.H. Faulding & Co. LimitedAnalgesic pharmaceutical composition
US5773031A (en)1996-02-271998-06-30L. Perrigo CompanyAcetaminophen sustained-release formulation
WO1997033566A2 (en)1996-03-121997-09-18Alza CorporationComposition and dosage form comprising opioid antagonist
US5766623A (en)1996-03-251998-06-16State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State UniversityCompactable self-sealing drug delivery agents
US6136864A (en)1996-04-102000-10-24Warner-Lambert CompanyDenaturants for sympathomimetic amine salts
GB9611328D0 (en)1996-05-311996-08-07Zeneca LtdPharmaceutical compositions
ES2334768T1 (en)1996-06-262010-03-16Board Of Regents, The University Of Texas System EXTRUIBLE PHARMACEUTICAL FORMULATION OF CONTROLLED LIBERATION.
US5972381A (en)1996-06-281999-10-26Schering CorporationSolid solution of an antifungal agent with enhanced bioavailability
US20010003588A1 (en)*1996-09-122001-06-14Smithkline Beecham CorporationControlled release dosage form of [R-(Z)]-alpha-(methoxyimino)-alpha-(1-azabicyclo[2.2.2.]oct-3-yl)acetonitrile monohydrochloride
JP2002511777A (en)1996-10-282002-04-16ゼネラル ミルズ,インコーポレイテッド Embedding and encapsulation of controlled release particles
US5939090A (en)1996-12-031999-08-173M Innovative Properties CompanyGel formulations for topical drug delivery
US5968547A (en)1997-02-241999-10-19Euro-Celtique, S.A.Method of providing sustained analgesia with buprenorphine
US5948787A (en)1997-02-281999-09-07Alza CorporationCompositions containing opiate analgesics
US6120751A (en)1997-03-212000-09-19Imarx Pharmaceutical Corp.Charged lipids and uses for the same
US6124282A (en)1997-05-222000-09-26Sellers; Edward M.Drug formulations
US6153621A (en)*1997-06-232000-11-28The University Of Kentucky Research FoundationCombined antagonist compositions
RS49982B (en)1997-09-172008-09-29Euro-Celtique S.A.,Synergistic analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
US6294194B1 (en)1997-10-142001-09-25Boehringer Ingelheim Pharmaceuticals, Inc.Method for extraction and reaction using supercritical fluids
US6066339A (en)1997-10-172000-05-23Elan Corporation, PlcOral morphine multiparticulate formulation
EP1035834B1 (en)1997-12-052002-04-17Alza CorporationOsmotic dosage form comprising first and second coats
NZ505193A (en)1997-12-222003-03-28Euro Celtique SOpioid agonist/antagonist combinations
US6251430B1 (en)1998-02-042001-06-26Guohua ZhangWater insoluble polymer based sustained release formulation
US6143278A (en)1998-02-232000-11-07Elkhoury; George F.Topical application of opioid analgesic drugs such as morphine
US6245357B1 (en)1998-03-062001-06-12Alza CorporationExtended release dosage form
GB9814411D0 (en)1998-07-031998-09-02Mw Encap LimitedCapsule sealing system
JP2002520377A (en)*1998-07-142002-07-09イーエム インダストリーズ インコーポレイテッド Microdispersed drug delivery system
TR200101216T2 (en)*1998-11-022001-08-21Marla J. Church Multiple particle modified release composition
IE981008A1 (en)1998-12-022000-06-14Fuisz Internat LtdMicroparticles Containing Water Insoluble Active Agents
EP1005863A1 (en)1998-12-042000-06-07SynthelaboControlled-release dosage forms comprising a short acting hypnotic or a salt thereof
US6248363B1 (en)1999-11-232001-06-19Lipocine, Inc.Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6395300B1 (en)*1999-05-272002-05-28Acusphere, Inc.Porous drug matrices and methods of manufacture thereof
US6406745B1 (en)1999-06-072002-06-18Nanosphere, Inc.Methods for coating particles and particles produced thereby
US6309663B1 (en)1999-08-172001-10-30Lipocine Inc.Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
BE1012795A3 (en)1999-07-232001-03-06Barco Elbicon N VUse of optical waveguide technology in a sort device.
DK1623703T3 (en)1999-10-292011-11-28Euro Celtique Sa Controlled release hydrocodone formulations
AR031682A1 (en)1999-11-192003-10-01Reckitt Benckiser Helthcare Uk PHARMACEUTICAL COMPOSITIONS
US20020131988A1 (en)*1999-12-162002-09-19Foster Todd P.Pharmaceutical implant containing immediate-release and sustained-release components and method of administration
US6491949B2 (en)*2000-01-142002-12-10Osmotica Corp.Osmotic device within an osmotic device
US6458384B2 (en)*2000-02-232002-10-01Impetus AgPharmaceutical with predetermined activity profile
US6419954B1 (en)2000-05-192002-07-16Yamanouchi Pharmaceutical Co., Ltd.Tablets and methods for modified release of hydrophilic and other active agents
HUP0301668A2 (en)2000-08-102003-09-29Delsys Pharmaceutical CorporationImproved solid pharmaceutical dosage formulation of hydrophobic drugs
FR2812906B1 (en)*2000-08-102002-09-20Snecma Moteurs AXIAL RETAINER RING OF A FLANGE ON A DISC
US6344215B1 (en)2000-10-272002-02-05Eurand America, Inc.Methylphenidate modified release formulations
RU2253452C2 (en)2000-10-302005-06-10Эро-Селтик С.А.Controlled-release hydrocodon composition
CA2440641A1 (en)2001-03-132002-09-19Anand R. BaichwalChronotherapeutic dosage forms containing glucocorticosteroid
US6780424B2 (en)2001-03-302004-08-24Charles David ClaudeControlled morphologies in polymer drug for release of drugs from polymer films
US20020187192A1 (en)2001-04-302002-12-12Yatindra JoshiPharmaceutical composition which reduces or eliminates drug abuse potential
UA81224C2 (en)2001-05-022007-12-25Euro Celtic S ADosage form of oxycodone and use thereof
US20030035839A1 (en)2001-05-152003-02-20Peirce Management, LlcPharmaceutical composition for both intraoral and oral administration
EP1271783B1 (en)*2001-06-292013-07-31Sicronic Remote KG, LLCFPGA with a simplified interface between the program memory and the programmable logic blocks
US20030021841A1 (en)2001-07-022003-01-30Matharu Amol SinghPharmaceutical composition
ES2292775T3 (en)2001-07-062008-03-16Penwest Pharmaceuticals Co. FORMULATIONS OF PROLONGED RELEASE OF OXIMORPHONE.
US20150031718A1 (en)2001-08-062015-01-29Purdue Pharma L.P.Pharmaceutical Formulation Containing Opioid Agonist, Opioid Antagonist and Gelling Agent
US7842307B2 (en)2001-08-062010-11-30Purdue Pharma L.P.Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
WO2003015531A2 (en)2001-08-062003-02-27Thomas GruberPharmaceutical formulation containing dye
US6585997B2 (en)2001-08-162003-07-01Access Pharmaceuticals, Inc.Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20040253310A1 (en)2001-09-212004-12-16Gina FischerMorphine polymer release system
EP1429730A4 (en)2001-09-262010-06-16Penwest Pharmaceuticals CompanOpioid formulations having reduced potential for abuse
US20030091630A1 (en)2001-10-252003-05-15Jenny Louie-HelmFormulation of an erodible, gastric retentive oral dosage form using in vitro disintegration test data
JP2005035888A (en)2001-10-252005-02-10Ta Stevia Co LtdSubstance for ameliorating anaphylactic type allergic symptom and method for producing the same
FR2831435A1 (en)2001-10-262003-05-02Oreal SPINABLE MATERIAL, SPINABLE COSMETIC COMPOSITION, MAKEUP COMPOSITION AND MAKEUP PROCESS
US20040126428A1 (en)*2001-11-022004-07-01Lyn HughesPharmaceutical formulation including a resinate and an aversive agent
US20030194420A1 (en)*2002-04-112003-10-16Richard HollProcess for loading a drug delivery device
WO2003092676A1 (en)2002-04-292003-11-13The General Hospital CorporationCompositions and methods for preventing abuse of orally administered medications
WO2003101431A1 (en)*2002-06-042003-12-11J.B. Chemicals & Pharmaceuticals Ltd.Pharmaceutical composition for controlled drug delivery system
US7776314B2 (en)2002-06-172010-08-17Grunenthal GmbhAbuse-proofed dosage system
NZ522071A (en)2002-10-182005-07-29Patrick Joseph SilcockHydrolysed casein phosphoprotein preparations for bioactive metal ion delivery and teeth remineralisation
US20050186139A1 (en)2002-10-252005-08-25Gruenenthal GmbhAbuse-proofed dosage form
CA2510465A1 (en)2002-12-182004-07-08Pain TherapeuticsOral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
DE602004031096D1 (en)2003-03-262011-03-03Egalet As MORPHINE SYSTEM WITH CONTROLLED RELEASE
BRPI0409652A (en)2003-04-242006-04-25Jagotec Ag tablet, pharmaceutical packaging, disease treatment method, and tablet preparation method
US8906413B2 (en)*2003-05-122014-12-09Supernus Pharmaceuticals, Inc.Drug formulations having reduced abuse potential
US20040241234A1 (en)2003-06-022004-12-02Alpharma, Inc.Controlled release press-coated formulations of water-soluble active agents
US20060165790A1 (en)2003-06-272006-07-27Malcolm WaldenMultiparticulates
US8075872B2 (en)2003-08-062011-12-13Gruenenthal GmbhAbuse-proofed dosage form
DE102004020220A1 (en)2004-04-222005-11-10Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE10336400A1 (en)2003-08-062005-03-24Grünenthal GmbH Anti-abuse dosage form
DE102004032051A1 (en)2004-07-012006-01-19Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
DE10361596A1 (en)2003-12-242005-09-29Grünenthal GmbH Process for producing an anti-abuse dosage form
US20070048228A1 (en)2003-08-062007-03-01Elisabeth Arkenau-MaricAbuse-proofed dosage form
GB0320351D0 (en)2003-08-292003-10-01Yates Donald HA preparation against flying insects that bite
WO2005027878A1 (en)2003-09-192005-03-31Penwest Pharmaceuticals Co.Delayed released dosage forms
EP1663156A2 (en)2003-09-192006-06-07Penwest Pharmaceuticals CompanyChronotherapeutic dosage forms
CN102697704A (en)*2003-09-262012-10-03阿尔扎公司Controlled release formulations of opioid and nonopioid analgesics
DE102004032049A1 (en)2004-07-012006-01-19Grünenthal GmbH Anti-abuse, oral dosage form
DE102004032103A1 (en)2004-07-012006-01-19Grünenthal GmbH Anti-abuse, oral dosage form
GB2418854B (en)2004-08-312009-12-23Euro Celtique SaMultiparticulates
US20060177380A1 (en)*2004-11-242006-08-10Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20060110327A1 (en)*2004-11-242006-05-25Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20080152595A1 (en)*2004-11-242008-06-26Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of orally administered pharmaceutical products
DE102005005449A1 (en)2005-02-042006-08-10Grünenthal GmbH Process for producing an anti-abuse dosage form
WO2006133733A1 (en)*2005-06-132006-12-21Flamel TechnologiesOral dosage form comprising an antimisuse system
FR2898056B1 (en)*2006-03-012012-01-20Ethypharm Sa SQUEEZE-RESISTANT TABLETS TO PREVENT UNLAWFUL MISUSE
US9023400B2 (en)2006-05-242015-05-05Flamel TechnologiesProlonged-release multimicroparticulate oral pharmaceutical form
US20080069891A1 (en)*2006-09-152008-03-20Cima Labs, Inc.Abuse resistant drug formulation
CA2658170A1 (en)2006-07-112008-01-17Mutual Pharmaceutical Company, Inc.Controlled-release formulations
SA07280459B1 (en)*2006-08-252011-07-20بيورديو فارما إل. بي.Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US20080176955A1 (en)2007-01-162008-07-24Victory Pharma, Inc.Combined administration of benzonatate and guaifenesin
DE102007011485A1 (en)*2007-03-072008-09-11Grünenthal GmbH Dosage form with more difficult abuse
US20080286343A1 (en)*2007-05-162008-11-20Dzenana CengicSolid form
US9044345B2 (en)2007-05-222015-06-02Brainlab AgNavigated placement of pelvic implant based on combined anteversion by applying Ranawat's sign or via arithmetic formula
JP2011506318A (en)2007-12-062011-03-03デュレクト コーポレーション Oral pharmaceutical formulation
MX2010006694A (en)*2007-12-172010-09-07Labopharm IncMisuse preventative, controlled release formulation.
US8377453B2 (en)*2008-03-112013-02-19Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8362029B2 (en)2008-12-312013-01-29Upsher-Smith Laboratories, Inc.Opioid-containing oral pharmaceutical compositions and methods
AP3815A (en)2010-12-222016-09-30Purdue Pharma LpEncased tamper resistant controlled release dosage forms

Patent Citations (102)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3173876A (en)*1960-05-271965-03-16John C ZobristCleaning methods and compositions
US3133132A (en)*1960-11-291964-05-12Univ CaliforniaHigh flow porous membranes for separating water from saline solutions
US3260646A (en)*1962-10-191966-07-12Ferring AbMedication with mechanism to prevent overdosage
US3276586A (en)*1963-08-301966-10-04Rosaen Filter CoIndicating means for fluid filters
US3980766A (en)*1973-08-131976-09-14West Laboratories, Inc.Orally administered drug composition for therapy in the treatment of narcotic drug addiction
US4088864A (en)*1974-11-181978-05-09Alza CorporationProcess for forming outlet passageways in pills using a laser
US4070494A (en)*1975-07-091978-01-24Bayer AktiengesellschaftEnteral pharmaceutical compositions
US4160020A (en)*1975-11-241979-07-03Alza CorporationTherapeutic device for osmotically dosing at controlled rate
US4385057A (en)*1978-10-201983-05-24Ab FerrosanDiphenylbutyl-piperazinecarboxamides in pharmaceutical compositions and methods
US4200098A (en)*1978-10-231980-04-29Alza CorporationOsmotic system with distribution zone for dispensing beneficial agent
US4285987A (en)*1978-10-231981-08-25Alza CorporationProcess for manufacturing device with dispersion zone
US4293539A (en)*1979-09-121981-10-06Eli Lilly And CompanyControlled release formulations and method of treatment
US4457933A (en)*1980-01-241984-07-03Bristol-Myers CompanyPrevention of analgesic abuse
US4424205A (en)*1982-03-181984-01-03The Procter & Gamble CompanyHydroxyphenylacetamides having analgesic and anti-irritant activity
US4389393A (en)*1982-03-261983-06-21Forest Laboratories, Inc.Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4389393B1 (en)*1982-03-261985-10-22
US4459278A (en)*1983-03-071984-07-10Clear Lake Development GroupComposition and method of immobilizing emetics and method of treating human beings with emetics
US4599342A (en)*1984-01-161986-07-08The Procter & Gamble CompanyPharmaceutical products providing enhanced analgesia
US4812446A (en)*1984-01-161989-03-14The Procter & Gamble CompanyPharmaceutical products providing enhanced analgesia
US4588580A (en)*1984-07-231986-05-13Alza CorporationTransdermal administration of fentanyl and device therefor
US4588580B1 (en)*1984-07-231989-01-03
US4588580B2 (en)*1984-07-231999-02-16Alaz CorpTransdermal administration of fentanyl and device therefor
US4610870A (en)*1984-10-051986-09-09E. R. Squibb & Sons, Inc.Controlled release formulation
US4806341A (en)*1985-02-251989-02-21Rutgers, The State University Of New JerseyTransdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US4666705A (en)*1985-06-031987-05-19E. R. Squibb & Sons, Inc.Controlled release formulation
US4769372A (en)*1986-06-181988-09-06The Rockefeller UniversityMethod of treating patients suffering from chronic pain or chronic cough
US4861598A (en)*1986-07-181989-08-29Euroceltique, S.A.Controlled release bases for pharmaceuticals
US4990341A (en)*1986-10-311991-02-05Euroceltique, S.A.Controlled release hydromorphone composition
US4957681A (en)*1988-04-151990-09-18Basf AktiengesellschaftPreparation of pharmaceutical mixtures
US5290816A (en)*1988-10-241994-03-01The United States Of America As Represented By The Secretary Of Health And Human ServicesComposition of resiniferatoxin and analogues thereof to cause sensory afferent C-Fiber and thermoregulatory desensitization
US5026556A (en)*1988-11-101991-06-25Norwich Eaton Pharmaceuticals, Inc.Compositions for the transdermal delivery of pharmaceutical actives
US5403868A (en)*1988-12-231995-04-04Sandoz Ltd.Capsaicin derivatives
US5330766A (en)*1989-01-061994-07-19F. H. Faulding & Co. LimitedSustained release pharmaceutical composition
US5059600A (en)*1989-03-311991-10-22Yale UniversityTreating habit disorders
US5114942A (en)*1989-03-311992-05-19Yale UniversityTreating habit disorders
US5240711A (en)*1989-11-291993-08-31Lts Lohmann Therapie-Systeme Gmbh & Co. KgTransdermal therapeutic system comprising as active component buprenorphine
US5225199A (en)*1990-04-241993-07-06Teijin LimitedPharmaceutical plasters
US5111942A (en)*1990-04-251992-05-12Didier BernardinDisplay tray for aligned articles
US5130311A (en)*1990-11-201992-07-14Adir Et CompagnieOxazolopyridine compounds, compositions and use
US5149538A (en)*1991-06-141992-09-22Warner-Lambert CompanyMisuse-resistive transdermal opioid dosage form
US5215758A (en)*1991-09-111993-06-01Euroceltique, S.A.Controlled release matrix suppository for pharmaceuticals
US6572885B2 (en)*1991-12-242003-06-03Euro-Celtique, S.A.Orally administrable opioid formulations having extended duration of effect
US5286493A (en)*1992-01-271994-02-15Euroceltique, S.A.Stabilized controlled release formulations having acrylic polymer coating
US5639476A (en)*1992-01-271997-06-17Euro-Celtique, S.A.Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5514680A (en)*1992-06-221996-05-07The State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences UniversityGlycine receptor antagonists and the use thereof
US5324351A (en)*1992-08-131994-06-28EuroceltiqueAqueous dispersions of zein and preparation thereof
US5356467A (en)*1992-08-131994-10-18Euroceltique S.A.Controlled release coatings derived from aqueous dispersions of zein
US5604260A (en)*1992-12-111997-02-18Merck Frosst Canada Inc.5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5556838A (en)*1993-01-281996-09-17Virginia Commonwealth UniversityInhibiting the development of tolerance to and/or dependence on an addictive substance
US5321012A (en)*1993-01-281994-06-14Virginia Commonwealth University Medical CollegeInhibiting the development of tolerance to and/or dependence on a narcotic addictive substance
US5502058A (en)*1993-03-051996-03-26Virginia Commonwealth UniversityMethod for the treatment of pain
US5409944A (en)*1993-03-121995-04-25Merck Frosst Canada, Inc.Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5536752A (en)*1993-06-241996-07-16Merck Frosst Canada Inc.Phenyl heterocycles as COX-2 inhibitors
US5550142A (en)*1993-06-241996-08-27Merck Frosst Canada Inc.Phenyl heterocycles as cox-2 inhibitors
US5436265A (en)*1993-11-121995-07-25Merck Frosst Canada, Inc.1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5500227A (en)*1993-11-231996-03-19Euro-Celtique, S.A.Immediate release tablet cores of insoluble drugs having sustained-release coating
US6024982A (en)*1993-11-232000-02-15Euro-Celtique, S.A.Immediate release tablet cores of insoluble drugs having sustained-release coating
US5672360A (en)*1993-11-231997-09-30Purdue Pharma, L.P.Method of treating pain by administering 24 hour oral opioid formulations
US5616601A (en)*1994-07-281997-04-01Gd Searle & Co1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en)*1994-08-291996-05-28Merck Frosst Canada, Inc.Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en)*1994-09-291997-01-14The Dupont Merck Pharmaceutical CompanyProstaglandin synthase inhibitors
US5741524A (en)*1995-01-091998-04-21Edward Mendell Co., Inc.Sustained-release formulations utilizing pharmaceutical excipient having improved compressibility
US5552422A (en)*1995-01-111996-09-03Merck Frosst Canada, Inc.Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
US5604253A (en)*1995-05-221997-02-18Merck Frosst Canada, Inc.N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
US5510368A (en)*1995-05-221996-04-23Merck Frosst Canada, Inc.N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en)*1995-05-221997-06-17Merck Frosst Canada, Inc.N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5762963A (en)*1995-06-071998-06-09Emory UniversityMethod and compositions for controlling oral and pharyngeal pain using capsaicinoids
US6440464B1 (en)*1996-06-102002-08-27Viva Life ScienceNutritive composition for cardiovascular health containing fish oil, garlic, rutin, capsaicin, selenium, vitamins and juice concentrates
US6277398B1 (en)*1997-05-272001-08-21Endo Pharmaceuticals Inc.Analgesic drug composition containing a capsaicinoid and potentiator therefor
US5891919A (en)*1997-09-191999-04-06Burlington Bio-Medical & Scientific Corp.Denatonium capsaicinate and methods of producing the same
US20030059471A1 (en)*1997-12-152003-03-27Compton Bruce JonOral delivery formulation
US6627635B2 (en)*1997-12-222003-09-30Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6375957B1 (en)*1997-12-222002-04-23Euro-Celtique, S.A.Opioid agonist/opioid antagonist/acetaminophen combinations
US6228863B1 (en)*1997-12-222001-05-08Euro-Celtique S.A.Method of preventing abuse of opioid dosage forms
US6593367B1 (en)*1998-08-052003-07-15Brookhaven Science AssociatesTreatment of addiction and addiction-related behavior
US20030170181A1 (en)*1999-04-062003-09-11Midha Kamal K.Method for preventing abuse of methylphenidate
US6352721B1 (en)*2000-01-142002-03-05Osmotica Corp.Combined diffusion/osmotic pumping drug delivery system
US6696088B2 (en)*2000-02-082004-02-24Euro-Celtique, S.A.Tamper-resistant oral opioid agonist formulations
US6559159B2 (en)*2001-02-012003-05-06Research Triangle InstituteKappa opioid receptor ligands
US20030004177A1 (en)*2001-05-112003-01-02Endo Pharmaceuticals, Inc.Abuse-resistant opioid dosage form
US20030064122A1 (en)*2001-05-232003-04-03Endo Pharmaceuticals, Inc.Abuse resistant pharmaceutical composition containing capsaicin
US20030026838A1 (en)*2001-06-262003-02-06Farrell John J.Tamper-proof narcotic delivery system
US20050063909A1 (en)*2001-08-062005-03-24Euro-Celtique, S.A.Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030124185A1 (en)*2001-08-062003-07-03Benjamin OshlackPharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent
US20030068375A1 (en)*2001-08-062003-04-10Curtis WrightPharmaceutical formulation containing gelling agent
US20030068392A1 (en)*2001-08-062003-04-10Richard SacklerPharmaceutical formulation containing opioid agonist, opioid antagonist and irritant
US20030068370A1 (en)*2001-08-062003-04-10Richard SacklerPharmaceutical formulation containing irritant
US20030064099A1 (en)*2001-08-062003-04-03Benjamin OshlackPharmaceutical formulation containing bittering agent
US20030068276A1 (en)*2001-09-172003-04-10Lyn HughesDosage forms
US20030125347A1 (en)*2001-11-022003-07-03Elan Corporation PlcPharmaceutical composition
US20030126428A1 (en)*2001-12-282003-07-03Liu Fang-ChengLifm algorithm for security association database lookup in IPSEC application
US20050106249A1 (en)*2002-04-292005-05-19Stephen HwangOnce-a-day, oral, controlled-release, oxycodone dosage forms
US20040131552A1 (en)*2002-09-202004-07-08Alpharma, Inc.Sequestering subunit and related compositions and methods
US20050020613A1 (en)*2002-09-202005-01-27Alpharma, Inc.Sustained release opioid formulations and method of use
US20050214223A1 (en)*2002-10-252005-09-29Gruenenthal GmbhAbuse-safeguarded dosage form
US20040151791A1 (en)*2002-11-152004-08-05Ricardo Mayo-AlvarezPharmaceutical composition
US20030124061A1 (en)*2003-01-102003-07-03Roberts Richard H.Pharmaceutical safety dosage forms
US20050112067A1 (en)*2003-11-262005-05-26Vijai KumarMethods and compositions for deterring abuse of opioid containing dosage forms
US7201920B2 (en)*2003-11-262007-04-10Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of opioid containing dosage forms
US20070166234A1 (en)*2003-11-262007-07-19Acura Pharmaceuticals, Inc.Methods and compositions for deterring abuse of opioid containing dosage forms
US20050163717A1 (en)*2004-01-232005-07-28Birch Point Medical, Inc.Abuse potential reduction in abusable substance dosage form
US20060018837A1 (en)*2004-07-262006-01-26Victory Pharma, Inc.Pharmaceutical compositions and methods for the prevention of drug misuse

Cited By (108)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9707179B2 (en)2001-09-212017-07-18Egalet Ltd.Opioid polymer release system
US9694080B2 (en)2001-09-212017-07-04Egalet Ltd.Polymer release system
US8808745B2 (en)2001-09-212014-08-19Egalet Ltd.Morphine polymer release system
US9675610B2 (en)2002-06-172017-06-13Grünenthal GmbHAbuse-proofed dosage form
US10369109B2 (en)2002-06-172019-08-06Grünenthal GmbHAbuse-proofed dosage form
US9375428B2 (en)2003-03-262016-06-28Egalet Ltd.Morphine controlled release system
US9884029B2 (en)2003-03-262018-02-06Egalet Ltd.Morphine controlled release system
US8877241B2 (en)2003-03-262014-11-04Egalet Ltd.Morphine controlled release system
US10130591B2 (en)2003-08-062018-11-20Grünenthal GmbHAbuse-proofed dosage form
US10058548B2 (en)2003-08-062018-08-28Grünenthal GmbHAbuse-proofed dosage form
US9629807B2 (en)2003-08-062017-04-25Grünenthal GmbHAbuse-proofed dosage form
US11224576B2 (en)2003-12-242022-01-18Grünenthal GmbHProcess for the production of an abuse-proofed dosage form
US11844865B2 (en)2004-07-012023-12-19Grünenthal GmbHAbuse-proofed oral dosage form
US10675278B2 (en)2005-02-042020-06-09Grünenthal GmbHCrush resistant delayed-release dosage forms
US10729658B2 (en)2005-02-042020-08-04Grünenthal GmbHProcess for the production of an abuse-proofed dosage form
US8846086B2 (en)2006-08-252014-09-30Purdue Pharma L.P.Tamper resistant dosage forms
US9486412B2 (en)2006-08-252016-11-08Purdue Pharma L.P.Tamper resistant dosage forms
US8894987B2 (en)2006-08-252014-11-25William H. McKennaTamper resistant dosage forms
US8894988B2 (en)2006-08-252014-11-25Purdue Pharma L.P.Tamper resistant dosage forms
US8911719B2 (en)2006-08-252014-12-16Purdue Pharma LpTamper resistant dosage forms
US11298322B2 (en)2006-08-252022-04-12Purdue Pharma L.P.Tamper resistant dosage forms
US9770417B2 (en)2006-08-252017-09-26Purdue Pharma L.P.Tamper resistant dosage forms
US8834925B2 (en)2006-08-252014-09-16Purdue Pharma L.P.Tamper resistant dosage forms
US8821929B2 (en)2006-08-252014-09-02Purdue Pharma L.P.Tamper resistant dosage forms
US9084816B2 (en)2006-08-252015-07-21Purdue Pharma L.P.Tamper resistant dosage forms
US9095615B2 (en)2006-08-252015-08-04Purdue Pharma L.P.Tamper resistant dosage forms
US9095614B2 (en)2006-08-252015-08-04Purdue Pharma L.P.Tamper resistant dosage forms
US9101661B2 (en)2006-08-252015-08-11Purdue Pharma L.P.Tamper resistant dosage forms
US8815289B2 (en)2006-08-252014-08-26Purdue Pharma L.P.Tamper resistant dosage forms
US11304908B2 (en)2006-08-252022-04-19Purdue Pharma L.P.Tamper resistant dosage forms
US10076499B2 (en)2006-08-252018-09-18Purdue Pharma L.P.Tamper resistant dosage forms
US10076498B2 (en)2006-08-252018-09-18Purdue Pharma L.P.Tamper resistant dosage forms
US9763933B2 (en)2006-08-252017-09-19Purdue Pharma L.P.Tamper resistant dosage forms
US11826472B2 (en)2006-08-252023-11-28Purdue Pharma L.P.Tamper resistant dosage forms
US11904055B2 (en)2006-08-252024-02-20Purdue Pharma L.P.Tamper resistant dosage forms
US9486413B2 (en)2006-08-252016-11-08Purdue Pharma L.P.Tamper resistant dosage forms
US11304909B2 (en)2006-08-252022-04-19Purdue Pharma L.P.Tamper resistant dosage forms
US9492389B2 (en)2006-08-252016-11-15Purdue Pharma L.P.Tamper resistant dosage forms
US9492390B2 (en)2006-08-252016-11-15Purdue Pharma L.P.Tamper resistant dosage forms
US9492393B2 (en)2006-08-252016-11-15Purdue Pharma L.P.Tamper resistant dosage forms
US9492392B2 (en)2006-08-252016-11-15Purdue Pharma L.P.Tamper resistant dosage forms
US9492391B2 (en)2006-08-252016-11-15Purdue Pharma L.P.Tamper resistant dosage forms
US9775808B2 (en)2006-08-252017-10-03Purdue Pharma L.P.Tamper resistant dosage forms
US9545380B2 (en)2006-08-252017-01-17Purdue Pharma L.P.Tamper resistant dosage forms
US11938225B2 (en)2006-08-252024-03-26Purdue Pharm L.P.Tamper resistant dosage forms
US9775811B2 (en)2006-08-252017-10-03Purdue Pharma L.P.Tamper resistant dosage forms
US9775810B2 (en)2006-08-252017-10-03Purdue Pharma L.P.Tamper resistant dosage forms
US9763886B2 (en)2006-08-252017-09-19Purdue Pharma L.P.Tamper resistant dosage forms
US9775809B2 (en)2006-08-252017-10-03Purdue Pharma L.P.Tamper resistant dosage forms
US11964056B1 (en)2006-08-252024-04-23Purdue Pharma L.PTamper resistant dosage forms
US12246094B2 (en)2006-08-252025-03-11Purdue Pharma L.P.Tamper resistant dosage forms
US12280152B2 (en)2006-08-252025-04-22Purdue Pharma L.P.Tamper resistant dosage forms
US9775812B2 (en)2006-08-252017-10-03Purdue Pharma L.P.Tamper resistant dosage forms
US9770416B2 (en)2006-08-252017-09-26Purdue Pharma L.P.Tamper resistant dosage forms
US20090081290A1 (en)*2006-08-252009-03-26Purdue Pharma L.P.Tamper resistant dosage forms
US8722086B2 (en)2007-03-072014-05-13Gruenenthal GmbhDosage form with impeded abuse
US9642809B2 (en)2007-06-042017-05-09Egalet Ltd.Controlled release pharmaceutical compositions for prolonged effect
US9750701B2 (en)2008-01-252017-09-05Grünenthal GmbHPharmaceutical dosage form
US8377453B2 (en)2008-03-112013-02-19Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8668929B2 (en)2008-03-112014-03-11Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)2008-03-112013-02-12Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8394408B2 (en)2008-03-112013-03-12Depomed, Inc.Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US9161917B2 (en)2008-05-092015-10-20Grünenthal GmbHProcess for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US9005660B2 (en)2009-02-062015-04-14Egalet Ltd.Immediate release composition resistant to abuse by intake of alcohol
US9358295B2 (en)2009-02-062016-06-07Egalet Ltd.Immediate release composition resistant to abuse by intake of alcohol
US9023394B2 (en)2009-06-242015-05-05Egalet Ltd.Formulations and methods for the controlled release of active drug substances
US20110038930A1 (en)*2009-07-222011-02-17Grunenthal GmbhHot-melt extruded pharmaceutical dosage form
US10493033B2 (en)2009-07-222019-12-03Grünenthal GmbHOxidation-stabilized tamper-resistant dosage form
US9925146B2 (en)2009-07-222018-03-27Grünenthal GmbHOxidation-stabilized tamper-resistant dosage form
US10080721B2 (en)2009-07-222018-09-25Gruenenthal GmbhHot-melt extruded pharmaceutical dosage form
US8597681B2 (en)2009-12-222013-12-03Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9198861B2 (en)2009-12-222015-12-01Mallinckrodt LlcMethods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US9636303B2 (en)2010-09-022017-05-02Gruenenthal GmbhTamper resistant dosage form comprising an anionic polymer
US10300141B2 (en)2010-09-022019-05-28Grünenthal GmbHTamper resistant dosage form comprising inorganic salt
US9433582B2 (en)2011-05-172016-09-06Mallinckrodt LlcGastric retentive extended release pharmaceutical compositions
US8658631B1 (en)2011-05-172014-02-25Mallinckrodt LlcCombination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en)2011-05-172014-06-03Mallinckrodt LlcGastric retentive extended release pharmaceutical compositions
US8858963B1 (en)2011-05-172014-10-14Mallinckrodt LlcTamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9539328B2 (en)2011-05-172017-01-10Mallinckrodt LlcTamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US9468636B2 (en)2011-05-172016-10-18Mallinckrodt LlcCombination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US9629837B2 (en)2011-05-172017-04-25Mallinckrodt LlcPharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US9050335B1 (en)2011-05-172015-06-09Mallinckrodt LlcPharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia
US10201502B2 (en)2011-07-292019-02-12Gruenenthal GmbhTamper-resistant tablet providing immediate drug release
US10864164B2 (en)2011-07-292020-12-15Grünenthal GmbHTamper-resistant tablet providing immediate drug release
US10695297B2 (en)2011-07-292020-06-30Grünenthal GmbHTamper-resistant tablet providing immediate drug release
US9655853B2 (en)2012-02-282017-05-23Grünenthal GmbHTamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9993422B2 (en)2012-04-182018-06-12SpecGx LLCImmediate release, abuse deterrent pharmaceutical compositions
US10335373B2 (en)2012-04-182019-07-02Grunenthal GmbhTamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en)2012-05-112018-09-04Gruenenthal GmbhThermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9044402B2 (en)2012-07-062015-06-02Egalet Ltd.Abuse-deterrent pharmaceutical compositions for controlled release
US10485753B2 (en)2012-07-122019-11-26SpecGx LLCExtended release, abuse deterrent pharmaceutical compositions
US11096887B2 (en)2012-07-122021-08-24SpecGx LLCExtended release, abuse deterrent pharmaceutical compositions
US9730885B2 (en)2012-07-122017-08-15Mallinckrodt LlcExtended release, abuse deterrent pharmaceutical compositions
US9301918B2 (en)2013-03-152016-04-05Mallinckrodt LlcAbuse deterrent solid dosage form for immediate release with functional score
US9737490B2 (en)2013-05-292017-08-22Grünenthal GmbHTamper resistant dosage form with bimodal release profile
US10154966B2 (en)2013-05-292018-12-18Grünenthal GmbHTamper-resistant dosage form containing one or more particles
US10624862B2 (en)2013-07-122020-04-21Grünenthal GmbHTamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10449547B2 (en)2013-11-262019-10-22Grünenthal GmbHPreparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en)2014-05-122018-03-13Grünenthal GmbHTamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en)2014-05-262018-01-23Grünenthal GmbHMultiparticles safeguarded against ethanolic dose-dumping
US11517521B2 (en)2014-07-032022-12-06SpecGx LLCAbuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US11583493B2 (en)2014-07-032023-02-21SpecGx LLCAbuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US11617712B2 (en)2014-07-032023-04-04SpecGx LLCAbuse deterrent immediate release formulations comprising non-cellulose polysaccharides
US9855263B2 (en)2015-04-242018-01-02Grünenthal GmbHTamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en)2015-09-102020-11-24Grünenthal GmbHProtecting oral overdose with abuse deterrent immediate release formulations
US9849125B1 (en)2015-11-032017-12-26Banner Lifie Sciences LLCAnti-overingestion dosage forms
US10335375B2 (en)2017-05-302019-07-02Patheon Softgels, Inc.Anti-overingestion abuse deterrent compositions
US11478426B2 (en)2018-09-252022-10-25SpecGx LLCAbuse deterrent immediate release capsule dosage forms

Also Published As

Publication numberPublication date
US20150005333A1 (en)2015-01-01
US20160000718A1 (en)2016-01-07
US20190117580A1 (en)2019-04-25
US20160151291A1 (en)2016-06-02
US20180125788A1 (en)2018-05-10
US20160151360A1 (en)2016-06-02
US20160151499A1 (en)2016-06-02
US20140228390A1 (en)2014-08-14
US8999961B2 (en)2015-04-07
US20160151356A1 (en)2016-06-02
US9867783B2 (en)2018-01-16
US20150265607A1 (en)2015-09-24
US20190070119A1 (en)2019-03-07
US20150283129A1 (en)2015-10-08
US20170020864A1 (en)2017-01-26
US20150182628A1 (en)2015-07-02
US20160058716A1 (en)2016-03-03
US11135171B2 (en)2021-10-05
US9877924B2 (en)2018-01-30
US9034376B2 (en)2015-05-19
US20160151357A1 (en)2016-06-02
US9517207B2 (en)2016-12-13
US20190110996A1 (en)2019-04-18
US20150265603A1 (en)2015-09-24
US9861582B2 (en)2018-01-09
US20150273064A1 (en)2015-10-01
US9867784B2 (en)2018-01-16
US10064824B2 (en)2018-09-04
US20130217716A1 (en)2013-08-22
US20130261145A1 (en)2013-10-03
US20120108622A1 (en)2012-05-03
US20200138720A1 (en)2020-05-07
US10076497B2 (en)2018-09-18
US9968559B2 (en)2018-05-15
US20180147151A1 (en)2018-05-31
US10130586B2 (en)2018-11-20
US9861583B2 (en)2018-01-09
US20030068375A1 (en)2003-04-10
US8337888B2 (en)2012-12-25
US20130261144A1 (en)2013-10-03
US20160151297A1 (en)2016-06-02
US20160151289A1 (en)2016-06-02
US20160000723A1 (en)2016-01-07
US20140371257A1 (en)2014-12-18
US20170065525A1 (en)2017-03-09
US20160000776A1 (en)2016-01-07
US20180055771A1 (en)2018-03-01
US8389007B2 (en)2013-03-05
US20130245055A1 (en)2013-09-19
US10537526B2 (en)2020-01-21
US8871265B2 (en)2014-10-28
US20150374631A1 (en)2015-12-31
US9757341B2 (en)2017-09-12
US9308170B2 (en)2016-04-12
US20170296533A1 (en)2017-10-19
US20150238481A1 (en)2015-08-27
US9044435B2 (en)2015-06-02
US9387174B2 (en)2016-07-12
US20160000712A1 (en)2016-01-07
US20130261143A1 (en)2013-10-03
US20180021262A1 (en)2018-01-25
US20150140083A1 (en)2015-05-21
US20150265606A1 (en)2015-09-24
US20190015341A1 (en)2019-01-17
US20160000717A1 (en)2016-01-07
US10071057B2 (en)2018-09-11
US8529948B1 (en)2013-09-10
US20170020863A1 (en)2017-01-26
US20160151290A1 (en)2016-06-02
US20090081287A1 (en)2009-03-26
US20150147391A1 (en)2015-05-28
US20160000719A1 (en)2016-01-07
US20160151502A1 (en)2016-06-02
US20140357657A1 (en)2014-12-04
US20170065524A1 (en)2017-03-09
US20150265602A1 (en)2015-09-24
US20140213606A1 (en)2014-07-31
US9040084B2 (en)2015-05-26
US10206881B2 (en)2019-02-19
US20150283128A1 (en)2015-10-08
US20150283130A1 (en)2015-10-08
US8609683B2 (en)2013-12-17
US9308171B2 (en)2016-04-12
US20150265605A1 (en)2015-09-24
US20170112765A1 (en)2017-04-27
US20160151277A1 (en)2016-06-02
US10064825B2 (en)2018-09-04
US20150265604A1 (en)2015-09-24
US9060976B2 (en)2015-06-23
US20150374628A1 (en)2015-12-31
US20150273065A1 (en)2015-10-01
US9693961B2 (en)2017-07-04
US20150148319A1 (en)2015-05-28
US20130303494A1 (en)2013-11-14
US20150005331A1 (en)2015-01-01
US9872836B2 (en)2018-01-23
US20150283250A1 (en)2015-10-08
US20160151358A1 (en)2016-06-02
US10500160B2 (en)2019-12-10
US20160151355A1 (en)2016-06-02
US9387173B2 (en)2016-07-12

Similar Documents

PublicationPublication DateTitle
US10064825B2 (en)Pharmaceutical formulation containing gelling agent
US9155717B2 (en)Pharmaceutical formulation containing irritant

Legal Events

DateCodeTitleDescription
STCBInformation on status: application discontinuation

Free format text:ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

ASAssignment

Owner name:THE P.F. LABORATORIES, INC., NEW JERSEY

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PURDUE PHARMA L.P.;REEL/FRAME:029515/0964

Effective date:20121220

Owner name:PURDUE PHARMA L.P., CONNECTICUT

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PURDUE PHARMA L.P.;REEL/FRAME:029515/0964

Effective date:20121220

Owner name:PURDUE PHARMACEUTICALS L.P., NORTH CAROLINA

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PURDUE PHARMA L.P.;REEL/FRAME:029515/0964

Effective date:20121220

ASAssignment

Owner name:PURDUE PHARMA L.P., CONNECTICUT

Free format text:ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:THE P.F. LABORATORIES, INC.;PURDUE PHARMA TECHNOLOGIES, INC.;REEL/FRAME:048932/0651

Effective date:20190408


[8]ページ先頭

©2009-2025 Movatter.jp